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Abstract 
 
The Cancer Stem Cell (CSC) theory suggests that cancers arise from and are maintained by a 
subpopulation of cancer cells with stem cell properties. Molecular chaperones are key components of 
cellular regulation. The overexpression of chaperones has become synonymous with cancer cells with 
chaperones being recognized as bona fide anti-cancer drug targets. Although chaperone activity has 
been characterized in cancer cells, very little is known about the cellular functions of chaperones in 
cancer stem cells. We set out to compare the expression of selected molecular chaperones in non-stem 
cancer cell and cancer stem cell enriched populations isolated from breast cancer lines, in order to 
identify chaperones differentially expressed between the two populations for further biological 
characterization. In order to isolate breast cancer stem cells from the MCF-7 and MDA-MB-231 breast 
cancer cell lines, three cancer stem cell isolation and identification techniques were utilized based on 
(1) cell surface marker expression (CD44+/CD24- and CD44+/CD24-/EpCAM+ phenotypes), (2) 
aldehyde dehydrogenase enzyme activity (ALDHHi) and (3) ability to grow in anchorage-independent 
conditions. The MDA-MB-231 and MCF-7 breast cancer cell lines displayed CD44+/CD24- cell 
populations with the MCF-7 cell line additionally displaying a large CD44+/CD24-/EpCAM+ 
population. Although both cell lines showed similar ALDHHi populations, they differed substantially 
with respect to anchorage-independent growth. MCF-7 cells were able to form anchorage-independent 
colonies while the MDA-MB-231 cell line was not. Anchorage-independent MCF-7 cells showed 
enrichment in CD44+/CD24- and CD44+/CD24-/EpCAM+ cells compared to adherent MCF-7 cells, 
and were selected for gene expression studies. Gene expression studies identified 22 genes as being 
down-regulated at the mRNA level in the anchorage-independent MCF-7 cells, while only 2 genes 
(BAG1 and DNAJC12) were up-regulated. The down-regulation of selected chaperones in anchorage 
independent MCF-7 cells was confirmed at the protein level for selected chaperones, including 
DNAJB6, a type II DNAJ protein shown to be involved in the regulation of Wnt signaling.  In order to 
characterize the effect of DNAJB6 expression on BCSCs we developed a pCMV mammalian 
expression plasmid for both DNAJB6 isoforms (DNAJB6L and DNAJB6S). We successfully 
constructed mutants of the conserved histidine-proline-aspartic acid (HPD) motif of the J domain of 
 iii 
DNAJB6S and DNAJB6L. These constructs will allow the analysis of the role of DNAJB6 in cancer 
stem cell function. To the best of our knowledge, this is the first report to focus on the comparative 
expression of molecular chaperones in normal and cancer stem cell enriched breast cancer 
populations. 
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Chapter 1 : Literature Review  
 2 
1.1 Cancer Stem Cells: Origin, Evidence and Significance 
 
1.1.1 Cancer Stem Cell Theory 
 
The Cancer Stem Cell (CSC) theory has come to the forefront of oncology research in the past decade 
with the identification of putative CSC populations in numerous malignant tissue types and a growing 
understanding of CSC biology. Cancers have and still are being therapeutically treated as homogenous 
entities, with therapies developed to target and destroy as many cancer cells as possible based on the 
assumption that all cells of the tumour possess shared biological properties (such a rapid proliferation). 
All cancer cells were considered to have equal potential to re-establish the cancer upon 
xenotransplantation (Reya et al, 2001). However, cell biological studies on malignant cells suggested 
an alternative hypothesis that had consequences for the design of future therapeutic strategies. Cancers 
have not only been found to be comprised of heterogeneous cell populations (Park et al, 1971), but 
additionally there was a requirement for xenotransplantation of large cell numbers in order for re-
establishment of the disease in vivo (Bruce and van der Gaag, 1962). These observations opposed the 
theories of homogeneity and stochastic tumour organization for two reasons. Firstly, although 
heterogeneity can and does, to a certain extent, arise from frequent mutations due to genome 
instability and rapid proliferation (Grady, 2006), the extent of the heterogeneity observed suggested an 
organization similar to the hierarchical organization seen in normal non-cancerous tissues. Secondly, 
the requirement for the use of large cell numbers for disease re-establishment (Bruce and van der 
Gaag, 1962; Hamburger and Salmon, 1977) was unexpected if every cell displayed an equal capability 
to re-establish the disease. Both results led to the theory that within the hierarchical cellular 
organization of cancers, there resided a population of cancer cells that mimic the role of stem cells in 
normal tissue hierarchies (Reya et al, 2001). 
 
The hierarchy model of cancer organization (Figure 1.A) follows the organization of normal non-
cancerous tissues and ultimately led to the development of the CSC theory, a theory describing cancer 
development, maintenance and organization as being driven by a subset of cancer cells that displayed 
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stem-like properties (Reya et al, 2001; Dick, 2003). The definition of a CSC as described by the 
theory relied on the similarity of biological properties with normal tissue stem cells, cells that are 
responsible for the development and maintenance of normal tissues. Stem cells are required for 
organogenesis (organ development) and tissue maintenance through the constant replacement of dying 
cells (Alison and Islam, 2009). There are two types of stem cells, namely embryonic and adult/somatic 
stem cells. Pluripotent embryonic stem cells are capable of differentiation into all cells making up an 
organism (Sylvester and Longmaker, 2004). Adult/somatic stem cells arise from the partial 
differentiation of embryonic stem cells and are tissue-specific stem cells capable of differentiation into 
all cell types within the given tissue. These cells are believed to be present for the entire lifespan of the 
organism and are primarily involved in the maintenance and rejuvenation of tissues. Examples of adult 
stem cells are the stem cells lining the crypts of the intestine which are responsible for the 
replenishment of the intestinal lining cells (Barker et al, 2007). Stem cells are primitive cells capable 
of both self-renewal and differentiation (Reya et al, 2001; Lobo et al, 2006; Alison and Islam, 2009). 
Self-renewal is the ability to divide to generate cells displaying identical properties of the stem cell 
parent, a characteristic that suggests that only stem cells can generate stem cells and ensures that stem 
cells are maintained in the population. Differentiation is the process of cellular maturation whereby 
cells lose the ability to undergo self-renewal and develop functional and phenotypic characteristics of 
mature cells or differentiated cells (Figure 1.A). Differentiation results in the loss of stem cell 
characteristics, meaning that the ability to form the numerous cells making up a specific tissue system 
is lost. Stem cells are capable of both symmetric cell division, generating daughter stem cells 
displaying identical properties to the parent cell; and asymmetric cell division, resulting in the 
formation of a daughter stem cell and a daughter cell that undergoes differentiation resulting in the 
loss of stem cell characteristics (Lobo et al, 2006). The balance between self-renewal and 
differentiation is strictly regulated by both the intracellular and extracellular environment, often 
referred to as the stem cell niche. This is the microenvironment in which cell-to-cell interactions occur 
that regulate the fate of stem cells (Scadden, 2006; Morrison and Spradling, 2008). 
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Figure 1| Cancer Stem Cell theory of tumour organization. 
(A) Hierarchical structure of cancer cell organization. Cancer stem cells form the apex of tumour heterogeneity (black 
circles) and are capable of self-renewal (generating additional CSCs) and differentiation (generating tumour 
heterogeneity). Only CSCs are capable of initiating tumour formation. As cells become more differentiated they lose 
the ability to self-renew with self-renewal and differentiation properties seen as inversely proportional. (B) Current 
anti-cancer therapies (non-CSC targeting) target the majority tumour cells that form the non-stem cancer cell 
population. Due to natural intrinsic resistance the CSC population is able to survive the treatment and together with 
tumour initiating properties are capable of reforming the tumour. Cancer stem cell targeting therapies may either 
target the CSC population specifically or both the non-stem and CSC populations. By removing the population 
responsible for tumour development and maintenance the tumour will be unable to maintain its growth leading to 
shrinkage of the tumour and a long-term cure without possibility of recurrence. 
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1.1.2 Definition of a Cancer Stem Cell 
 
Cancer stem cells are cancer cells that, like normal tissue stem cells, are capable of both self-renewal, 
to maintain the CSC population, and differentiation which leads to cancer cell heterogeneity. This 
process of cancer cell differentiation has been hypothesized as being an abnormal and uncontrolled 
process with further expansion of the observed heterogeneity arising from mutations occurring as a 
result of the rapid proliferation (Clarke et al, 2006). The defining characteristic of CSCs was the 
ability to reform a cell mass with an identical heterogeneity to the cell mass from which the CSC was 
isolated, suggesting the capability of these cells to undergo both self-renewal and differentiation 
processes (Reya et al, 2001; Clarke et al, 2006; Dick, 2008). Just as normal tissue stem cells are 
responsible for organogenesis and tissue maintenance, so it is thought that CSCs are responsible for 
tumour development (tumourigenesis) and maintenance (Dalerba et al, 2007). The term ‘cancer stem 
cell’ is used to discriminate those cancer cells that share properties with stem cells from non-stem 
cancer cells, which do not possess stem-like characteristics. The term ‘cancer stem cell’ does not mean 
that the cancer stem cell responsible for tumour initiation was necessarily derived from a somatic stem 
cell. There is much controversy as to which cells give rise to CSC, as it is plausible that stem cells 
may accumulate oncogenic mutations through the long term cell lifespan that lead to cancer initiation, 
or that non-stem cancer cells may dedifferentiate to gain stem-like functions leading to cancer 
initiation (Bjerkvig et al, 2005; Clarke et al, 2006, Takahashi et al, 2007; Chaffer et al, 2011). 
 
1.1.3 Evidence of Cancer Stem Cells 
 
In order to positively identify the presence of CSC populations, researchers needed to be able to 
isolate a distinct population of cells from malignant tissue and demonstrate the exclusive ability of this 
population to reform malignant tissue with an identical heterogeneity to the original malignant mass in 
vivo. Lapidot and colleagues (1994) are credited with providing the first evidence for the presence of 
CSCs in research performed on acute myeloid leukaemia (AML). They identified the presence of a 
definable subset of AML cells, identified by positive expression of CD34 and the absence or lack of 
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expression of CD38 (CD34+/CD38- phenotype) that displayed the exclusive ability to initiate AML 
formation in vivo in severe combined immunodeficient (SCID) mice (Lapidot et al, 1994). It is 
interesting that the AML CSC population shared an identical phenotype (CD34+/CD38-) with normal 
tissue stem cells from the hematopoietic system (Huang and Terstappen, 1994). Subsequent work by 
Bonnet and Dick (1997) led to the development of what is now seen as the gold standard CSC assay, 
whereby they both confirmed the presence of and determined the frequency of AML CSC using the 
non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse xenotransplantation 
model (Bonnet and Dick, 1997). These studies identified a small yet definable population of cancer 
cells that were cable of self-renewal and re-establishing the disease in vivo, properties seen as defining 
characteristics of CSCs. 
 
The first evidence of CSCs in solid tumours was provided in breast cancer, where breast cancer stem 
cells (BCSCs) were identified based on the expression of CD44 and absence or lack of expression of 
CD24 (CD44+/CD24- phenotype) (Al-Hajj et al, 2003). Cells displaying this phenotype were capable 
of in vivo tumour formation from as few as 200 cells (Al-Hajj et al, 2003). Since this important study, 
evidence of CSCs based on the expression of defined cell surface markers has been provided for a 
multitude of primary solid tumours including brain tumours (CD133+) (Singh et al, 2003), prostate 
cancer (CD133+/CD44+) (Collins et al, 2005), colon cancer (CD133+) (Ricci-Vitiani et al, 2007), 
head and neck squamous cell carcinoma (CD44+) (Prince et al, 2007), pancreatic cancer 
(CD44+/EpCAM+/CD24+) (Li et al, 2007) and melanoma (CD20+) (Fang et al, 2005). From these 
putative CSC populations, there was evidence of markers common to CSCs from different tissue 
tumour types. CSCs have also been isolated from cancer cell lines, most notably a number of breast 
cancer cell lines (Fillmore and Kuperwasser, 2007; Engelmann et al, 2008; Charafe-Jauffret et al, 
2009b), prostate cancer cell lines (Pfeiffer and Schalken, 2010) and lung cancer cell lines (Ho et al, 
2007). 
 
Several different markers have subsequently been used to distinguish and isolate BCSCs from non-
stem breast cancer cells. Studies by Wright and colleagues (2008) revealed CSC heterogeneity 
amongst BRCA-1 deficient mouse mammary tumours, with the isolation of two distinct BCSC 
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populations based on the CD44+/CD24- phenotype and the expression of CD133 (CD133+) (Wright 
et al, 2008), a marker normally associated with brain (Singh et al, 2003), prostate (Collins et al, 2005) 
and colon CSCs (Ricci-Vitiani et al, 2007). Both these CSC populations displayed high expression of 
aldehyde dehyodrogenase 1 (ALDH1+) (Wright et al, 2008), a result in line with gene expression 
studies on CD44+/CD24- BCSCs (Shipitsin et al, 2007). High expression and activity of ALDH1 
isoforms has been used to isolate stem/progenitor cells from both normal and malignant breast tissue 
(Ginestier et al, 2007). Comparison between ALDH1+ BCSCs and CD44+/CD24- BCSCs from 
primary tumours revealed a small overlapping CD44+/CD24-/ALDH1+ population that was more 
tumourigenic than both the ALDH1+ and CD44+/CD24- populations. Interestingly the CD44+/CD24-
/ALDH1- population was unable to form tumours in vivo, a result that implied that the tumourigenicity 
of the CD44+/CD24- population was attributed to the presence of the small ALDH1+ subpopulation 
within the CD44+/CD24- population (Ginestier et al, 2007). Although these markers are commonly 
used for isolating CSCs, they are by no means the only markers of CSCs. In particular for breast 
cancer, there is much contention surrounding which markers should be used for isolating CSC 
populations (Lawson et al, 2009).  
 
Perhaps more importantly, it should be noted that all BCSC populations identified and isolated display 
the same functional properties of in vitro and in vivo tumourigenicity irrespective of the markers used 
to isolate the population (Al-hajj et al, 2003; Ponti et al, 2005; Engelmann et al, 2008; Wright et al, 
2008). Stem-like cells have been isolated and propagated based on the ability to grow anchorage-
independently in serum-free non-adherent conditions for both normal neural and breast tissue 
(Reynolds and Rietze, 2005; Dontu et al, 2003), whereas non-stem cells undergo anoikis, a 
programmed cell death associated with loss of adhesion (Frisch and Frances, 1994; Frisch and 
Screaton, 2001). Ponti and colleagues adapted this technique to isolate anchorage-independent stem-
cell enriched colonies derived from primary breast tumour tissues (Ponti et al, 2005). Anchorage-
independent colonies (termed mammospheres or tumourspheres) were found to be comprised of 
between 95 to 98 % CD44+/CD24- expressing cells (Ponti et al, 2005), the most widely accepted 
BCSC phenotype (Al-Hajj et al, 2003). The anchorage independent colonies were capable of in vivo 
tumour formation at limiting cell dilutions and expressed high levels of Oct4 (Ponti et al, 2005), a 
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gene associated with stem cells (Yeom et al, 1996). Anchorage-independent growth properties have 
also allowed for the isolation of BCSCs from breast cancer cell lines (Cariati et al, 2008). Colonies 
isolated from breast cancer cell lines were enriched in in vivo tumour forming cells and side 
population cells (Cariati et al, 2008).  
 
The side population (SP) refers to a small population of cells within a tissue that is capable of 
effluxing the fluorescent DNA-binding dyes Hoechst 33342 and Rhodamine 123 and as a result this 
population can be isolated based on low fluorescence levels with the aid of a flow cytometer (Dean et 
al, 2005). The reason for the efflux of these fluorescent dyes was due to the high expression levels of 
ATP-binding cassette (ABC) drug transporter family proteins, especially ABCG2 (Dean et al, 2005). 
Side population cells have been found to be enriched in both normal (Goodell et al, 1996; Alvi et al, 
2002) and malignant (Patrawala et al, 2005; Cariati et al, 2008) stem-like cells. Side population cells 
isolated from breast cancers are capable of generating tumours in vivo (Patrawala et al, 2005), 
tumoursphere formation (Cariati et al, 2008) and are enriched in cells displaying the putative BCSC 
phenotype CD44+/CD24- (Engelmann et al, 2008). 
 
The clinical importance of CSCs is related to their potential roles in cancer development as well as 
metastasis and cancer relapse (Dean et al, 2005). One aspect of the theory suggested that CSCs are 
naturally resistant to chemotherapy due to their slow cell cycling state, capacity for DNA repair and 
ABC transporter expression levels (Dean et al, 2005). As such this population may survive anti-cancer 
therapy and be capable of regenerating a new cancer mass due to the inherent tumourigenicity. Studies 
by Li et al (2008) provided evidence of this natural resistance when they found that chemotherapy 
treatment enriched for CD44+/CD24- cells with increased efficiencies in anchorage-independent 
growth and in vivo tumour formation (Li et al, 2008). A possible means of targeting CSCs is through 
the targeting of specific signaling pathways. Breast cancer stem cells have been found to be reliant on 
several signaling pathways, thereby providing a potential specific target for this therapeutically 
important population. Both CD44+/CD24- and tumoursphere-derived BCSC populations have been 
shown to be dependent on Notch receptor signaling, in particular Notch4 (Harrison et al, 2010). Notch 
signaling also plays an important role in normal mammary stem cell self-renewal and progenitor cell 
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proliferation (Dontu et al, 2004). Side population cells, expressing high levels of drug transporters, 
have been found to show high activity of Akt signaling with inhibition of the signaling pathway 
leading to reduction in side population cell number (Zhou et al, 2007). Current anti-cancer therapies 
are designed to target the bulk (differentiated) cells within a tumour, while CSCs, capable of initiating 
tumour growth, are largely unaffected (Figure 1.B) due to the activation of cell survival signaling 
pathways and overexpression of anti-apoptosis genes. Understanding the fundamental biology of 
CSCs and how they function may provide insight as to new therapies that can target these cells thereby 
removing the regeneration and maintenance abilities of cancers. 
 
1.2 Molecular Chaperones 
 
Molecular chaperones can be described as regulatory proteins that are involved in maintaining protein 
homeostasis in the cell, in order to prevent apoptosis from occurring due to the build up of non-
functioning proteins which become toxic to the cell (Lindquist and Craig, 1988; Becker and Craig, 
1994). Chaperones and in particular the heat shock protein (HSP) family were first identified based on 
their overexpression upon heat treatment (Tissieres et al, 1974). Although initially described as being 
expressed as a stress response, chaperones are now understood to play vital housekeeping functions 
with many HSPs being constitutively expressed. The functions of molecular chaperones include (but 
are not limited to) suppression of aggregation, folding of nascent and damaged proteins, translocation 
of proteins into cellular compartments including the nucleus, mitochondria and endoplasmic 
reticulum, and assistance of protein degradation (Linquist and Craig, 1988; Becker and Craig, 1994). 
Of the molecular chaperone families, the Heat Shock Proteins (HSP) is the largest and best 
understood. The HSP family is comprised of several subfamilies including HSP90, HSPA and DNAJ. 
Many HSPs have essential roles under stressful conditions such as heat shock, as well as vital roles 
under physiological conditions (e.g. DNAJB1, HSPA8 and HSP90β; Vos et al, 2008). Chaperones 
usually carry out their functions as part of a multi-protein complex consisting of one or more 
chaperones, co-chaperones and other protein folding regulatory proteins (BAG, CCT and HSF 
families). Co-chaperones function in the regulation and stimulation of chaperone activity and in the 
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recruitment of other proteins involved in the multi-protein complex (Wall et al, 1994; van der Spuy et 
al, 2001; Felts and Toft, 2003). 
1.2.1 Heat shock protein 90 kDa (HSP90) 
 
HSP90 is one of the most abundant cellular proteins, making up approximately 1 to 2 % of total 
protein within a cell (Mahalingam et al, 2009). Although HSP90 by itself is seen as a chaperone, it is 
commonly understood to function as part of a multi-chaperone complex consisting of other chaperones 
(HSPA), co-chaperones and co-factors (DNAJ) (Sreedhar et al, 2004) with HSP90 functioning in this 
complex as a phosphorylated homodimer (Minami et al, 1991; Minami et al, 1994). There are 5 
HSP90 genes encoding for proteins of approximately 90 kDa in size with the exception of HSP90N. 
There are two cytosolic isoforms of HSP90 namely HSP90α (inducible) and HSP90β (constitutively 
expressed), as well as HSP90 isoforms located in the endoplasmic reticulum (GRP94) and the 
mitochondria (TRAP1). Recently an additional HSP90 member, HSP90N, has been described as a 
plasma membrane-associated isoform and differs from HSP90α and HSP90β by an N-terminal ATP 
binding domain truncation (Grammatikakis et al, 2002; Powers and Workman, 2007). HSP90 domains 
are highly conserved across isoforms with each member consisting of a well characterized N-terminal 
ATP binding domain (except HSP90N), a middle region consisting of ATP hydrolysis regulating and 
client binding domains, a C-terminal dimerization domain and a putative C-terminal ATP binding 
domain (Figure 2.A) (Podromou et al, 1997; Panaretou et al, 1998; Wandinger et al, 2008). 
Additionally HSP90α, HSP90β and GRP94 contain a charged linker region located between the N-
terminal ATPase and middle regions.  HSP90 functions include, but are not limited to, the regulation 
of protein conformation and stability, the transportation of proteins into cellular compartments and the 
stability of protein-protein interactions (Trepel et al, 2010). Although chaperones are generally 
considered to partake in active protein folding, HSP90 is unique in that the majority of its functioning 
is on folded or partially folded polypeptides, with the chaperone aiding in maturation of proteins rather 
than folding (Freeman and Morimoto, 1996; Csermley et al, 1998). As the chaperone has over 200 
client proteins (proteins with which HSP90 interacts), many of which are involved in signaling 
pathways (for example steroid receptors, kinases, cytoskeletal proteins and transcription factors), 
HSP90 plays a vital role in cellular homeostasis (Xu et al, 1993; Pratt et al, 1998).  
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1.2.2 Heat shock protein 70 kDa (HSPA) 
 
HSPA genes (HSP70, 70-kDa heat shock proteins) are commonly involved in nascent polypeptide 
folding and in the unfolding or degradation of misfolded or targeted proteins, amongst other functions 
(Kampinga and Craig, 2010). HSPA forms a critical component of the HSP90 pathway and is involved 
in HSP90-dependent signaling pathways. HSPAs function in a cyclical manner with multiple client 
association and dissociation cycles controlled by ATP hydrolysis and regulated by co-chaperones, 
most importantly DNAJ. HSPAs when associated to ATP show low client affinity, however J-domain 
stimulation of HSPA ATP hydrolysis to ADP increases the HSPA client affinity resulting in a stable 
HSPA-client complex (Greene et al, 1998; Michels et al, 1999; Fan et al, 2003). Nucleotide exchange 
factor (NEF) co-chaperones catalyze the exchange of ADP for ATP from the ATPase domain resulting 
in the release of the client protein (Sondermann et al, 2001). This process is repeated over numerous 
cycles in order for HSPAs to actively assist in protein de novo protein folding (Mayer and Bukau, 
2005). The HSP70 family in humans is comprised of 13 isoforms that share a relatively conserved 
structure with an N-terminal ATPase domain, a β-sheet structured substrate binding domain and an α-
helical C-terminus (Figure 2.B) (Kampinga and Craig, 2010). Like HSP90, several HSPA members 
show specific subcellular localization to the endoplasmic reticulum and mitochondria. 
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Figure 2| Domain architecture of HSP90, HSPA and DNAJ molecular chaperones. 
Conserved domain structures present in HSP90 (A), HSPA (B) and DNAJ (C) molecular chaperone 
families. ATPase, ATPase domain. Linker+, charged linker region. Client BD, client binding domain. 
Dimerization, dimerization domain. N-term, N-terminus. α C-term, α C-terminal lid. G/F, 
Glycine/Phenylalanine rich region. Cys-rich, Cysteine-rich region. 
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1.2.3 . DNAJ 
 
DNAJ are direct co-chaperones of HSPA where they function in the presentation of client peptides to 
HSPA and stimulation of the HSPA ATPase activity (Kampinga and Craig, 2010). Originally 
characterized according to the domain similarity to Escherichia coli DNAJ, human DNAJs vary both 
in domain architecture and molecular size, although all contain the highly conserved J-domain. The J-
domain is pivotal for the stimulation of the HSPA ATPase activity (Tsai et al, 1996; Hennessy et al, 
2000; Hennessy et al, 2005). The DNAJ family consists of 49 members and is divided into three 
subclasses based on structural similarities with E.coli DNAJ. Type I DNAJ (DNAJA isoforms) and 
Type II DNAJ (DNAJB isoforms) show high structural similarity to the canonical E.coli DNAJ, both 
consisting of an N-terminal J-domain, a glycine/phenylalanine rich region and a largely 
uncharacterized C-terminus believed to be the substrate binding domain (Lu and Cyr, 1992; Sha et al, 
2000). The only difference between these two subclasses is that Type I DNAJ (DNAJA), like the 
E.coli DNAJ, contain a cysteine repeat region (containing the motif CXXCXGXG where X is any 
amino acid) following the glycine-phenylalanine rich region, while Type II DNAJ (DNAJB) lack this 
region (Figure 2.C) (Cheetham and Caplan, 1998; Vos et al, 2008; Kampinga et al, 2009). Type III 
DNAJ (DNAJC isoforms) are highly diverse, most with the only commonality with Type I and Type II 
DNAJ being the presence of the J-domain (Figure 2.C) (located anywhere along the peptide) 
(Cheetham and Caplan, 1998; Vos et al, 2008; Kampinga et al, 2009).   
1.2.4 Chaperones as anti-cancer drug targets 
 
Many HSP90 client proteins are oncogenes and thus HSP90 has been described as the cancer 
chaperone (Whitesell and Lindquist, 2005). In many cases, these oncogenic client proteins induce 
oncogenesis as a result of mutations that affect the biological functions of the proteins. These mutants 
have been found to display a greater requirement for HSP90 activity in order to maintain the stability 
of the mutant (Shimamura et al, 2005; Whitesell and Lindquist, 2005), thereby perpetuating the 
influence that HSP90 has on cancer cells. Additionally, in cancer cells, HSP90 has been found to be 
present in a higher order activated complex that displays a greater affinity for HSP90 inhibitors when 
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compared to HSP90 from non-cancerous normal cells (Kamal et al, 2003). This specificity, combined 
with the overexpression of HSP90 in cancers (Jameel et al, 1992; Chant et al, 1995; Ciocca and 
Calderwood, 2005), the fact that HSP90 chaperones many oncogene client proteins and the greater 
requirement for HSP90 to stabilize oncogene proteins (Shimamura et al, 2005), makes HSP90 an 
attractive target in cancer therapeutics. However the main concern with targeting HSP90 is the effect 
that HSP90 inhibition has on non-cancerous cells, which is primarily due to the essential nature of 
HSP90 for eukaryotic cell survival (Bagatell and Lindquist, 2004; Whitesell and Lindquist, 2005). 
Recently cancer cells have been shown to be able to overcome HSP90 inhibition through an 
alternative chaperone compensation mechanism that results in the up-regulation of numerous 
chaperones and co-chaperones including HSPA and HSPB members (Maloney et al, 2007). HSPA 
family of chaperones have subsequently been identified as potential anti-cancer chaperone drug targets 
due to the over-expression in cancers (Chant et al, 1995; Ralhan and Kaur, 1995) and pivotal roles that 
HSPAs have been found to play in cell survival and proliferation (Kaur et al, 2000; Rohde et al, 
2005). Additionally support for HSPAs as drug target is provided by the HSP90 inhibitioin 
compensation mechanism whereby not only is HSPA overexpression a signature but HSPA function is 
capable of compensating for HSP90 inhibition resulting in cell survival (Bagatell et al, 2000; Evans et 
al, 2010). This compensatory function of HSPAs is also evident when specific members of the HSPA 
family are inhibited resulting in the up-regulation of alternate members capable of compensating for 
the inhibition (Powers et al, 2008). 
 
Together with HSP90 and HSPAs, there is evidence suggesting that DNAJ may also serve as anti-
cancer drug targets. Several DNAJs have been identified as playing significant roles in cancer cell 
biology through tumour property-promoting or tumour property-suppressing mechanisms (Table 1), or 
in the case of DNAJA3 regulating both promotion and suppression of tumour properties through the 
expression and activity of different isoforms (Syken et al, 1999; Cheng et al, 2005; Kim et al, 2004; 
Kim et al, 2005). The predominant effect of cancer-associated DNAJ functions centre around cell 
survival and apoptosis, in some cases promoting or associated with resistance to anti-cancer therapies 
(DNAJA1, DNAJA3 and DNAJB11; Table 1), or sensitizing cancer cells to anti-cancer therapies 
(DNAJA3, DNAJB4, DNAJC10 and DNAJC15; Table 1). 
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Table 1| DNAJ molecular chaperones function in cancer and expression in stem-like cells 
 
 
 
Adapted from Sterrenberg et al, 2011. 1 Gene expression comparison made between CD44+/CD24- BCSCs and normal 
breast tissue AIG, Anchorage-independent growth isolated. BC, Breast cancer. BCSC, Breast cancer stem cells. ER+, 
Estrogen receptor positive. hESC, Human embryonic stem cells. KSHV, Kaposi’s sarcoma-associated herpesvirus. 
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1.2.5 Chaperones in stem cells and CSC 
 
There is a paucity of data available on the role of chaperones in stem cell and CSC biology. As 
chaperones are seen as regulatory proteins within cells (Becker and Craig, 1994), it is likely that 
chaperones and chaperone-associated genes play vital roles in the highly regulated state of stem-like 
cells. Several functional and gene expression studies on stem cells, CSCs and stem-like associated 
signaling pathways, suggested that chaperones and chaperone-associated genes may play key roles in 
regulating stem-like nature of these cell types (Table 1). Numerous DNAJ genes have been found to 
be differentially expressed in embryonic stem cells versus normal tissue and several CSC-enriched 
populations versus non-stem cancer cells, with DNAJA1 (Van Hoof et al, 2006; Shipitsin et al, 2007; 
Rappa and Lorico, 2010) and DNAJC9 (Van Hoof et al, 2006; Rappa and Lorico, 2010) showing up-
regulation at both the mRNA and protein levels for both normal and cancerous stem-like tissues 
(Table 1). DNAJB6 displays tumour-suppressing properties through the regulation of the Wnt 
signaling pathway (Mitra et al, 2008; Mitra et al, 2010), a pathway that has found to be vital for both 
self-renewal and maintenance of the stem-line state of hematopoietic stem cells (Reya et al, 2003), 
embryonic stem cells (Sato et al, 2003), cutaneous CSCs (Malanchi et al, 2008) and colon CSCs 
(Vermeulen et al, 2010). Recently HSP90 has been suggested to regulate the Wnt signaling pathway 
through direct interactions with Glycogen synthase kinase 3β (GSK3β), AXIN and β-catenin (Cooper 
et al, 2011). HSP90 (in complex with HSP90 co-chaperone Cdc37) has additionally be found to 
stabilize and hence prevented the degradation of Fused, a hedgehog signaling molecule that promotes 
transcription of Hedgehog target genes through stabilization and nuclear localization of Gli 
transcription proteins (Murone et al, 2000; Kise et al, 2006). The association of HSP90 with Stat3 has 
been demonstrated in murine embryonic stem cells grown in the presence of leukaemia inhibitory 
factor (LIF) (Setati et al, 2010).  Mucin-1, a tumour specific antigen, forms a complex with both 
HSPA and HSP90 allowing for transportation into mitochondria (Ren et al, 2006). As Mucin-1 has 
been found to be expressed by both SP BCSCs and non-SP breast cancer cells (Engelmann et al, 
2008), it suggests that targeting of chaperones may allow for the dual targeting of both non-stem 
cancer cells and CSC populations. Indeed HSP90 inhibitors have shown to affect CSC population as 
suggested by the inhibited growth of glioma stem cells (Sauvageot et al, 2009) and leukemic stem 
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cells (Peng et al, 2007) after treatment with HSP90 inhibitors. Sauvageot and colleagues (2009) found 
that there was a greater growth inhibition effect on the CSC population compared to the non-stem 
cancer cell population which suggests that chaperones may offer a means of targeting both non-stem 
cancer cells and CSC through a single target. 
1.3 Problem statement 
 
The importance of chaperones has already been established in cancer cells with HSP90 and HSPA 
seen as bona fide drug targets. However there is increasing evidence that suggest that CSC populations 
display a natural resistance to anti-cancer therapies and therefore likely chaperone targeted therapies. 
There is additionally a lack of knowledge of the role that chaperones play in CSC biology. Indeed 
several of the DNAJ family members have been shown to play important role in both therapy 
resistance (DNAJA1, DNAJA3 and DNAJB11) and therapy sensitizing (DNAJA3, DNAJB4, 
DNAJC10 and DNAJC15) (Table 1). However not only does the impact of many chaperones in CSC 
biology remain to be determined, but also findings that alternative chaperones are capable of forming 
compensatory mechanisms as a result of the inhibition of specific chaperones such as the bona fide 
anti-cancer drug targets HSP90 and HSPA. Currently several gene expression studies have identified 
differential expression patterns of several DNAJ members between normal and stem-like cells in both 
malignant and normal tissues (Table 1). Although interesting, the studies only analyzed select 
chaperones and a complete chaperone expression pattern was not obtained. This is particularly the 
case with the DNAJ family as there are 49 members however the expression state of most of the 
family remains to determined.. 
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1.4 Hypothesis 
 
Breast cancer cell lines MCF7 and MDA-MB-231 contain putative CSC subpopulations that will 
express different levels of molecular chaperones compared to the whole cell population. Molecular 
chaperones that are either up-regulated or down-regulated may influence CSC properties.   
1.5 Aims 
 
• Identification and isolation of BCSC-enriched populations from the MCF-7 and MDA-MB-
231 breast cancer cell lines; 
• Comparison of molecular chaperone expression in whole cell and CSC-enriched populations 
from the MCF-7 breast cancer cell line;  
• Functional analysis of DNAJB6L-H31Q mutant on CSC properties of MCF7 cell line. 
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Chapter 2 : Materials and Methods 
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2.1 Materials 
 
MCF-7 (HTB-22) and MDA-MB-231 (HTB-26) breast cancer cell lines were a kind gift from Dr 
Sharon Prince, University of Cape Town, South Africa. All general reagents were purchased from 
Sigma-Aldrich (USA) or Saarchem (Merck, South Africa). Tissue culture reagents, 10 x Trypsin-
EDTA, foetal calf serum, Dulbecco’s Modified Eagle Medium with GlutaMAX™-I and Penicillin-
Streptomycin–Amphotericin (PSA) were purchased from Gibco (Invitrogen, UK) and Biowhittaker 
(UK). Tissue culture plasticware including ultra-low attachment culture flasks were purchased from 
Corning Incorporated (USA). Western Blotting power pack, Hybond Support Nitrocellullose and 
ChemidocTM EQ were purchased from Bio-Rad; UK. Antibodies and suppliers are listed in 
Appendix: Table 1. Other reagents not listed are referenced within text. 
2.2 Routine culture maintenance of adherent cancer cell 
lines  
 
MCF-7 and MDA-MB-231 breast cancer cell lines were routinely cultured in Dulbecco’s modified 
Eagle’s Medium (DMEM) with GlutaMAX (Gibco, Invitrogen) supplemented with 5% (v/v) FCS 
(Sigma) and 100 U/ml PSA at 37°C and 9% CO2.  
2.3 Anchorage-independent growth assay 
(mammosphere assay) 
 
Cells were lifted using trypsin solution [0.5% (v/v) trypsin in 1% (w/v) ethylenediaminetetraacetic 
acid (EDTA)], washed with phosphate-buffered saline [PBS; 137mM NaCl, 27mM KCl, 4.3 mM 
Na2HPO4, 4mM KH2PO4, pH 7] and viable cells counted using the trypan blue exclusion method and a 
hemocytometer. After counting, cells were washed a further two times in PBS and collected by 
centrifugation at 800 x g for 2 minutes. Cells were resuspended at the desired concentrations in 
anchorage-independent medium consisting of DMEM with GlutaMAX (Gibco, Invitrogen), 1 x B27 
supplement (Gibco, Invitrogen), 20 ng/ml basic fibroblast growth factor [bFGF] (Sigma, Germany), 
20 ng/ml epidermal growth factor [EGF] (Sigma, Germany), 5 µg/ml human recombinant insulin 
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(Novorapid), 10 µM Heparin (Sigma) and 100 U/ml PSA (Sigma, Germany). After resuspension, cells 
were passed through a 40 µm sieve twice to ensure single cell suspension before plating in ultra-low 
attachment culture flasks or plates (Corning, USA). Cells were grown for 8 days with media 
supplementation on days 3 and 6. Media supplementation comprised of the removal of half the growth 
medium and replacement with 2 x concentration of fresh anchorage-independent medium. After day 8, 
cells were harvested and washed with PBS and used in subsequent analyses. 
2.4 Cell surface marker analysis by flow cytometry 
 
Cells were lifted using trypsin solution as described previously, washed with PBS and viable cells 
counted using the trypan blue exclusion method and a haemocytometer. For anchorage-independent 
cells, cells were collected by centrifugation, washed, incubated with trypsin solution and counted as 
described previously. After counting, cells were resuspended to a final concentration of 5 x 106 cells/ 
ml in PBS. A total of 5 x 105 cells (100 µl) were placed into FACS tubes containing between 0.5 – 1 
µg of anti-CD44, anti-CD24 and anti-EpCAM antibodies or isotype matched control antibodies 
(Appendix Table 1). Unstained samples containing no antibodies were included. Samples were 
incubated at 4°C for 60 minutes. After incubation samples were washed twice with ice cold PBS and 
collected by centrifugation at 800 x g for 2 minutes. For analysis, the 488 nm laser (blue) was used to 
excite the fluorescein isothiocyanate (FITC) and phycoerythrin (PE) fluorophores with emissions 
recorded in the 530/30 filter channel (FITC) and the 585/42 filter channel (PE) respectively. The 633 
nm laser (red) was used to excite the allophycocyanin (APC) fluorophore with emission recorded in 
the 660/20 filter channel (APC). Compensation controls were used to establish compensation values 
for FITC and PE fluorescent overlap and this compensation was applied to all analyses. A total of 30 
000 live events were recorded for all samples. Data analyses were conducted on FlowJo software 
(Tree Star Inc, USA). Two-colour dot plots were constructed showing FITC (CD24) fluorescence on 
the y-axis and APC (CD44) fluorescence on the x-axis. Isotype controls were used to establish 
fluorescence threshold gates with the gates set on the isotype control to exclude the major population 
of cells. Gates were then copied onto the respective samples in order to determine the CD44/CD24 
expression profile of the sample. For EpCAM expression analyses, a histogram showing PE (EpCAM) 
 22 
fluorescence was displayed for the isotype control sample. A PE fluorescence threshold gate was set 
such that the major isotype control population was excluded. Using a two-colour dot plot of FITC 
(CD24)/APC (CD44) fluorescence, the PE (EpCAM) fluorescence of the CD44+/CD24- population 
(Q3) was displayed as a histogram. The PE fluorescence threshold gate was copied onto the respective 
EpCAM histograms in order to analyze the CD44+/CD24-/EpCAM+ phenotype. 
2.5 ALDEFLUOR assay analysis by flow cytometry 
 
All reagents were prepared as per the manufacturer’s instructions (StemCell Technologies) prior to 
first use. Cells were lifted with trypsin solution, washed with PBS and counted using the trypan blue 
exclusion method and a haemocytometer. For anchorage-independent cells, cells were washed and 
then incubated in PBS containing trypsin solution prior to counting. Cells were collected by 
centrifugation at 300 x g for 7 minutes and resuspended to a final concentration of 1 x 106 cells/ ml in 
ALDEFLUOR assay buffer. Activated ALDEFLUOR reagent was added to a final concentration of 
150 µM per 1 x 106 cells (test sample). From this solution, 5 x 105 cells were removed and added to a 
tube containing the ALDH inhibitor, diethylaminobenzaldehyde [DEAB] at a final concentration of 
150 µM (inhibitor control). Both test and inhibitor control samples were incubated at 37°C for 45 
minutes. Samples were washed twice in ice cold PBS and resuspended in ice cold ALDEFLUOR 
assay buffer. Samples were kept on ice until flow cytometry analysis using the FACSAria III (BD 
Biosciences, Belgium). For analysis, ALDEFLUOR fluorescence of 1 x 105 cells was measured by 
excitation using the 488 nm blue laser and emission detection in the FITC 530/30 filter channel. 
ALDEFLUOR analysis was performed using FACSDiva software (BD Biosciences, Belgium) with 
plots constructed by displaying side scatter height (SSC-H) profiles on y-axis versus FITC height 
(FITC-H) fluorescence profiles on the x-axis. The ALDEFLUOR positive gates were constructed 
using the inhibitor control sample and were standardized such that an ALDEFLUOR positive 
population of 0.1% was taken as acceptable background in the inhibitor control. The gates were then 
copied onto the related samples lacking the inhibitor. 
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2.6 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
 
Cell lysates were prepared in 5 x SDS-PAGE sample buffer without bromophenol blue [0.05M Tris-
HCL, 10% (v/v) glycerol, 5% (v/v) β-mercaptoethanol, 2% (w/v) SDS] and stored at -20°C until 
analysis. Prior to separation, protein concentrations were determined by absorbance at 280/360 using 
the Nanodrop2000 (Thermo Scientific). Lysates were diluted in 5x SDS-PAGE sample buffer 
containing 1% (w/v) bromophenol blue. Proteins were separated by SDS-PAGE using the protocol 
established by Laemmli (1970) using a 4% stacking (0.5M Tris-HCl, pH 6.8) and 12% resolving gel 
(1.5M Tris-HCl, pH 8.8). Gels were run at 100 V for approximately 1.5 hours in SDS-PAGE running 
buffer [0.25mM Tris, 192mM glycine, 1% (w/v) SDS]. 
2.7 Chemiluminescence-based western analysis 
 
Cell lysates separated during SDS-PAGE were transferred to nitrocellulose membrane (Towbin et al, , 
1979) at 100 V for 2 hours in transfer buffer [13 mM Tris-HCl, 100 mM glycine and 20 % (v/v) 
methanol] at 4°C. Protein transfer onto nitrocellulose was confirmed by Ponceau staining [0.5% (w/v) 
Ponceau S in 1% (v/v) glacial acetic acid]. Nitrocellulose membranes with transferred proteins were 
blocked with blotto solution [5% (w/v) fat free milk powder in Tris-buffered saline (TBS, 50 mM Tris, 
pH 7.5, 150 mM NaCl)] for 30 minutes and incubated with primary antibody (Appendix Table 1) 
overnight at 4°C, diluted to the manufacturer’s recommended dilution in blotto solution. The 
membrane was rinsed four times in TBS containing Tween-20 [TBST; 1% (v/v) Tween-20 in TBS] for 
15 minutes replacing the TBST each rinse. The membrane was incubated with species-specific 
secondary antibodies conjugated to horseradish peroxidase [HRP] at 1:5000 dilution in 5% (w/v) 
blotto solution for 45 minutes with agitation at room temperature. After secondary antibody 
incubation, the membrane was rinsed four times with TBST for 15 minutes each, replacing the TBST 
at each rinse. Detection of protein bands was performed using the Enhanced Chemiluminescence kit 
(GE Healthcare; UK) on the Chemidoc EQ system (Biorad; UK). Actin was used as the loading 
control in each case and densitometry was performed using ImageJ software. 
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2.8 Confocal microscopy analysis of anchorage-
independent and adherent MCF-7 breast cancer cells  
 
Anchorage-independent colonies and adherent cells were seeded into eight-well chambered coverslips 
overnight. Cells were fixed with a flash incubation in ice-cold methanol and left to air dry, after which 
the cells were washed in distilled water containing 1 µg/ml of DNA binding dye Hoechst 33342 to 
stain nuclei. The coverslips were mounted onto glass slides using Dako mounting media (Sigma). 
Differential contrast (DIC) and fluorescent images were taken using Zeiss LSM510 meta confocal 
microscope (Zeiss, Germany).  
2.9 Quantitative Reverse Transcriptase-Polymerase 
Chain Reaction (RT-PCR) for detection of molecular 
chaperones 
 
Total RNA was isolated from anchorage-independent and adherent MCF-7 breast cancer cells on day 
8 of growth using the NucleoSpin RNA/Protein isolation kit (Macherey-Nagel) according to 
manufacturer’s instructions. Total RNA was quantified by measuring the absorbance at 260nm using 
the NanoDrop2000 spectrophotometer (Thermo Scientific). Reverse Transcriptase PCR (RT-PCR) 
using the RT2 First Strand Kit (SA Biosciences) was used to convert 1 µg total RNA to cDNA for 
quantitative PCR (qPCR) analysis. After the RT-PCR procedure, cDNA was immediately added to the 
RT2 qPCR master mix (SA Biosciences) and equal volumes loaded into each well of a 96-well PCR 
Array plate (SA Biosciences) as per the manufacturer’s instructions. Plates were stored at -20°C 
overnight and centrifuged for 2 minutes at 1250 x g prior to the thermocycling. The thermocycling 
reaction was performed using a Bio-Rad iCycler with the following cycling parameters: Cycle 1 (1 
cycle), 95°C for 10 minutes; Cycle 2 (40 repeat cycles), 95°C for 15 seconds and 60°C for 1 minute; 
Cycle 3 (1 cycle), 95°C for 30 seconds; Cycle 4 (80 repeat cycles), starting temperature 55°C for 10 
seconds with an increase in temperature by 0.5°C increments after each repeat; Cycle 5 (1 cycle), 22°C 
incubation for unspecified period. Melt curves were performed to determine the presence of non-
specific or contaminating products that would influence the qPCR analysis, with all wells determined 
as showing single peak melting points indicating the absence of contaminating or non-specific product 
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formation. Data analysis was performed using the manufacturer’s online software (SA BioSciences; 
www.sabiosciences.com/pcrarraydataanalysis.php). 
2.10 Restriction digest identification of plasmid 
constructs 
 
The pcDNA-DNAJB6L and pcDNA-DNAJB6S constructs were a kind gift from Prof Harm 
Kampinga (Hageman and Kampinga, 2009). Plasmid DNA was extracted from filter paper by soaking 
the filter paper in 200 µl of TE buffer (10 mM Tris, 1 mM EDTA, HCl, pH 8) for 1 hour. Plasmid 
constructs were transformed into chemically competent JM109 E.coli cells. Fifty microlitres of 
competent cells and 1 µg of plasmid DNA were incubated on ice for 2 minutes prior to heat shock at 
42°C. After heat shock, cells were incubated on ice for a further 5 minutes. Cells were mixed with 500 
µl of 2 x YT broth (16 g/l Tryptone, 10 g/l Yeast extract, 5 g/l NaCl) and incubated at 37°C for 30 
minutes before 150 µl of the transformation was plated on 2 x YT agar plates and incubated overnight 
at 37°C.  Single colony transformants were used to inoculate 5 ml 2 x YT broth overnight at 37°C with 
shaking (200 rpm). Overnight culture of pCMV-HSJ1a was made by adding 100 µl of pCMV-HSJ1a 
glycerol stock to 5 ml 2 x YT broth and incubating overnight at 37°C with shaking (200 rpm). 
Plasmids were extracted using the QIAGEN Miniprep kit according to manufacturer’s instructions 
(QIAGEN). Restriction digest identification and confirmation of the pcDNA-DNAJB6 constructs was 
performed using BamHI and XhoI to release the DNAJB6L and DNAJB6S coding regions, and BamHI 
to release the HSJ1a coding region from the pCMV construct. Both plasmids were incubated without 
restriction enzymes, with BamHI or XhoI alone and a combination of BamHI and XhoI for 2 hours at 
37°C. Restriction digestion reactions were analysed using a 0.8% (w/v) agarose gel in Tris-Acetate-
EDTA buffer (TAE; 40 mM Tris, 20 mM acetic acid, 1 mM EDTA) containing 0.5 µg/ml ethidium 
bromide run at 100 V for approximately 1 hour. DNA bands were visualized using UV illumination 
with the ChemidocEQ (BioRAD). Approximate band size (in base pairs) was estimated using Pst1 
digestion of λ DNA. 
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2.11 Sub-cloning of DNAJB6L and DNAJB6S coding 
regions into pCMV plasmid 
 
The coding regions for DNAJB6L and DNAJB6S were released from the respective pcDNA 
constructs by BamHI and XhoI digestion at 37°C for 2 hours. Additionally the pCMV-HSJ1a construct 
was sequentially digested with BamHI and XhoI at 37°C for 1 hour each, in order to isolate the pCMV 
backbone with complimentary 5’ and 3’ overhangs to allow for ligation of the DNAJB6L and 
DNAJB6S coding regions into pCMV generating pCMV-DNAJB6L and pCMV-DNAJB6S. Digests 
were separated on a 0.8% (w/v) agarose TAE gel containing 0.5 µg/ml ethidium bromide at 100 V for 
approximately 1 hour. Bands were visualized on a UV transilluminator and bands corresponding to the 
sizes of DNAJB6L, DNAJB6S and pCMV backbone were excised and purified from the gel using the 
Zymoclean gel DNA recovery kit according to the manufacturer’s instructions (Zymo Research). 
Isolated DNAJB6L and DNAJB6S coding regions were ligated into the pCMV backbone to generate 
pCMV-DNAJB6L and pCMV-DNAJB6S constructs upon incubation at 4°C with 0.5 U T4 DNA 
ligase. Resulting ligations were transformed into DH5α E.coli cells and incubated overnight on YT 
agar containing 50 µg/ml kanamycin. Transformants were isolated as described previously and 
screened for the presence of the inserts by restriction digestion with BamHI and XhoI alone or in 
combination, in order to identify pCMV-DNAJB6L and pCMV-DNAJB6S transformants. The 
plasmids were confirmed by sequencing (Inqaba Biotec).  
2.12 Site-directed mutagenesis (SDM) of H31Q DNAJB6L 
and DNAJB6S mutants 
 
Complementary mutagenesis primers incorporating the H31Q mutation into the DNAJB6L and 
DNAJB6S coding regions were constructed using the Primer-BLAST on the NCBI website 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Purified pCMV-DNAJB6 plasmids (50 ng) were 
added to the SDM mix containing 125 ng of each primer (forward and reverse), 10 x Pfu reaction 
buffer, distilled water and 1mM dNTPs prior to the addition of 2.5 U Pfu DNA polymerase. After an 
initial denaturation step for 30 seconds at 95°C, the reaction mixture underwent 16 cycles of 
denaturation (30 seconds at 95°C), annealing (1 minute at 55°C) and extension (5 minutes at 68°C). 
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After thermocycling, the reaction mix was placed on ice for 2 minutes prior to DpnI (10 U) treatment 
at 37°C for one hour and subsequent transformation into competent E. coli DH5α. Single colony 
transformants were selected for plasmid isolation as previously described. Plasmids were screened for 
the presence of the mutation using restriction digestion with the enzyme BbvI and mutants confirmed 
by sequencing. 
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Chapter 3 : Identification and Isolation 
of BCSC-Enriched Populations from the 
MCF-7 and MDA-MB-231 Breast 
Cancer Cell Lines 
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3.1 Introduction 
 
Cancer stem cells (CSC) are thought to have a role in cancer initiation and development (Reya et al, 
2001; Visvader and Lindeman, 2008), resistance to common anti-cancer therapies (Dean et al, 2005; 
Li et al, 2008) and metastasis (Hermann et al, 2007, Pang et al, 2010). The CSC theory suggests that 
the large majority of the tumour is composed of non-stem tumour cells. Therefore, the biological 
characteristics of the minor CSC population (>1%) are often not observable when studying the tumour 
as a whole. Specific techniques are required in order to accurately identify the CSC population, and 
prevent the characteristics of the non-stem cancer cells, which represent the large majority of cells 
within a cancer, from masking the biological and functional properties of the CSCs (Clarke et al, 
2006; Charafe-Jaffret et al, 2009b). It must be noted that there are as yet no incontrovertible markers 
of CSCs, and therefore many of the available techniques that allow for the enrichment of CSC-like 
populations are accepted within the field (Al-Hajj et al, 2003; Ponti et al, 2005; Ginestier et al, 2007).  
 
The published methods for identification and isolation of CSCs can be separated into three groups, 
namely (1) cell surface marker-based techniques, relying on the expression of a single or combination 
of cell surface proteins; (2) functional-based techniques, which make use of stem-like biological 
properties to identify and isolate populations of cells; and (3) enzyme activity-based techniques that 
rely on both the expression and activity of a particular protein. Cell surface marker-based techniques 
usually rely on the expression of cell surface markers termed cluster of differentiation (CD) proteins 
(Clarke et al, 2006; Charafe-Jauffret et al, 2009b). Generally, but not always, a combination of 
markers (defined as a marker phenotype) is used to identify the desired CSC population. For BCSCs 
the most common and widely used marker phenotype is CD44+/CD24-, denoting the (high) 
expression of the CD44 cell surface protein and the lack (low) of expression of the CD24 cell surface 
protein (Al-Hajj et al, 2003; Fillmore and Kuperwasser, 2008). Functional-based techniques are based 
on stem-like biological properties of the cells and assess how closely the cells resemble stem-like cells 
in terms of biological function. The most widely used in vitro functional-based technique is the 
anchorage-independent growth assay, which tests the ability of adherent cells to survive and 
proliferate as spheres in an anchorage-independent serum-free environment. Somatic stem cells 
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isolated from normal adherent tissue are capable of surviving in a serum-free anchorage-independent 
environment whereas non-stem-like cells undergo a programmed cell death associated will loss of 
adhesion by adherent cells known as anoikis (Frisch and Francis, 1994; Frisch and Screaton, 2001; 
Dontu et al, 2003). The third category of CSC identification and isolation techniques relies on the 
expression of a family of proteins together with the altered or enhanced activity of these proteins for 
the identification of CSC enriched populations. Examples of these techniques include the side 
population and ALDEFLUOR assays. Both assays are fluorescence–based, with the side population 
assay identifying stem-like cells based on the efflux of the Hoechst 33342 dye due to overexpression 
of the ATP-binding cassette (ABC) family (especially the ABCG2 isoform) (Goodell et al, 1996). The 
ALDEFLUOR assay is based on the production of a fluorescent product by active aldehyde 
dehydrogenase (ALDH) isoforms, with the identification relying on the over-expression and activation 
of ALDH isoforms (especially the ALDH1 isoform), to detect a stem-like (ALDHHi) cell population 
(Ginestier et al, 2007). Both of these techniques allow for the identification and isolation of stem-like 
cells from both normal and malignant tissues (Ginestier et al, 2007). 
 
As there is much contention and debate surrounding the choice of CSC identification and isolation 
techniques, as well as this being the first study at Rhodes University to establish CSC identification 
and isolation techniques, we undertook to evaluate three BCSC identification and isolation techniques 
for the two breast cancer cell lines, MCF7 and MDA-MB-231. For the marker-based technique, two 
common BCSC phenotypes were analyzed, that being CD44+/CD24- and CD44+/CD24-/EpCAM+ 
phenotypes, where ‘+’ denotes the (high) expression of the cell surface marker while ‘-’ denotes the 
absence or low expression of the cell surface marker. The ALDEFLUOR assay was used as the 
enzyme activity-based technique while the anchorage-independent assay was used as the functional-
based CSC-enrichment technique. 
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3.2 Results 
 
The proportion of putative BCSC populations in the MCF-7 and MDA-MB-231 breast cancer cell 
lines were established and compared using three published CSC identification and isolation techniques 
(as described above). The MCF-7 breast cancer cell line was selected as it is a cell line already 
established in BCSC research (Charafe-Jauffret et al, 2009b). The MDA-MB-231 breast cancer cell 
line, derived from metastatic and basal cell type malignant breast tissue, was also included as it has 
been found to express high levels of the putative BCSC cell marker CD44 (Fillmore and Kuperwasser, 
2008).  
3.2.1 Cell surface marker-based identification of putative BCSC in MCF-7 
and MDA-MB-231 breast cancer cell lines 
 
The expression profiles of BCSC-associated cell surface markers (CD44, CD24 and EpCAM) were 
determined for the MCF-7 and MDA-MB-231 breast cancer cell lines using flow cytometry. Cell 
surface marker-based identification of BCSC is the most widely used technique for the isolation and 
characterization of the population. The currently accepted BCSC phenotype is the expression of CD44 
in the absence of CD24 expression (CD44+/CD24- phenotype). Additionally the combination of 
EpCAM expression (CD44+/CD24-/EpCAM+ phenotype) has been used to identify and isolate BCSC 
(Al-Hajj et al, 2003). In order to determine the BCSC phenotypes of the breast cancer cell lines, cells 
were triple stained for CD44, CD24 and EpCAM using fluorophore-conjugated antibodies against 
CD44 (APC), CD24 (FITC) and EpCAM (PE), allowing for the co-expression (phenotype) of the 
markers to be analyzed. Isotype controls, which consisted of non-specific antibodies of the same 
immunoglobulin class conjugated to the matched fluorophore, were used to identify non-specific 
antibody binding and to establish the fluorescence threshold gates (Figure 3). Figure 3 shows a 
diagrammatic representation of the gating strategy used to analyze the experimental data. The gating 
strategy began with the selection of the events (representing cells) to be analyzed (Figure 3: Panel I 
[Population Gate]). A population was selected based on the side scatter (SSC; Figure 3: Panel I [y-
axis]) and forward scatter (FSC; Figure 3: Panel I [x-axis]) fluorescence profile. Side scatter 
fluorescence was inversely proportional to cell granularity, therefore the more granular the event the 
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lower the SSC fluorescence. Granularity was an indication of cell viability with cell debris and cells 
undergoing apoptosis displaying a high granularity and thus low SSC fluorescence. Forward scatter 
refers to the size of the events and was directly proportional to FSC fluorescence. Therefore the larger 
the size of an event, the greater the FSC fluorescence recorded. The population gate on the SSC versus 
FSC plot (Figure 3: Panel I) was used to select only a subpopulation of events, considered to be live 
events, for subsequent analysis.  
 
Isotype controls were used to establish the fluorescence threshold gate for each of the antibodies in 
order to determine expression status of the marker. A two-colour dot plot, containing only the cells 
from the live gate (Figure 3; Panel I), of the isotype control sample was created displaying FITC 
(CD24) fluorescence (Figure 3: Panel II [y-axis]) and APC (CD44) fluorescence (Figure 3: Panel II [x-
axis]). A horizontal gate representing the FITC (CD24) fluorescence threshold (Figure 3: Panel III) 
was established such that the major population of events on the graph were excluded. This gate 
recorded any event displaying a FITC (CD24) fluorescence intensity below this threshold gate as 
being negative or not expressing the marker (i.e. CD24-), while every event with a FITC (CD24) 
fluorescence intensity greater than (above) the threshold fluorescence gate was recorded as showing 
positive expression of the marker (i.e. CD24+). A vertical gate representing the APC (CD44) 
fluorescence threshold was then established in the same manner to allow for the determination of 
CD44+ and CD44- cells (Figure 3: Panel IV). Events displaying an APC (CD44) fluorescence 
intensity lower (left) than the APC (CD44) threshold fluorescence gate were recorded as not 
expressing the marker (i.e. CD44-), while events displaying an APC (CD44) fluorescence intensity 
greater than the APC (CD44) threshold fluorescence gate were recorded as being positive for the 
marker (i.e. CD44+). The gating strategy resulted in the identification of four distinct quadrants that 
corresponded to the different CD44/CD24 expression phenotypes, namely Q1: CD44-/CD24+; Q2: 
CD44+/CD24+; Q3: CD44+/CD24- and Q4: CD44-/CD24- (Figure 3: Panel V). The gates were set 
using the isotype control sample and subsequently copied onto the test samples (sample containing 
antibodies specific to CD44 and CD24) to identify the CD44/CD24 phenotypic profile of the cell lines 
(Figure 3: Panel VI). 
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Figure 3| Fluorescence threshold gating strategy for CD44/CD24 BCSC cell surface marker 
analyses 
The population gate was constructed using the side scatter (SSC; y-axis) and forward scatter (FSC; x-axis) two colour 
dot plot so as to exclude events displaying high granularity (low SSC fluorescence) and large even size (high FSC 
fluorescence) which signify cells undergoing or having undergone apoptosis. Only the events within the population 
gate were analyzed. (II) The live events (Panel I) from the isotype control sample were analyzed for FITC (CD24; y-
axis) and APC (CD44; x-axis) fluorescence using a two-colour dot plot to determine non-specific binding of the 
respective immunoglobulin chain class to the surface of cells. (III) A FITC threshold gate was constructed such that the 
percentage of events in the isotype sample displaying positive FITC fluorescence was less then 0.1%. Any events with 
a fluorescence intensity above the threshold gate were recorded as being positive for the marker (CD24+), while 
events with a fluorescence intensity lower than the threshold were recorded as displaying low or no expression of the 
marker (CD24-). (IV) An APC threshold gate was constructed on the x-axis such that less then 0.1% of the isotype 
control sample displayed positive APC fluorescence. Events with a fluorescence intensity greater than the threshold 
(to the right) were recorded as displaying a positive expression for the marker (CD44+) while events with a 
fluorescence intensity lower than the threshold (to the left) were recorded as having low or no expression of the 
marker (CD44-). (V) The combination of both fluorescence threshold gates creates four quadrants (Q1- CD44-/CD24+; 
Q2- CD44+/CD24+; Q3- CD44+/CD24-; Q4- CD44-/CD24-) that can be used to characterize the expression phenotype 
of the two markers in question. (VI) The population and fluorescent threshold gates were then copied onto the 
respective test samples (sample containing antibodies specific for the markers) allowing for the identification of the 
proportions of cells with the different phenotypes to be identified.  
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As it is not possible to represent the three-colour staining on a single plot, the following gating 
strategy was used to identify the proportion of cells with the CD44+/CD24-/EpCAM+ phenotype 
associated with BCSCs. Using the isotype control sample, a histogram was constructed showing PE 
(EpCAM) fluorescence on the x-axis (Figure 4.A). Fluorescence threshold gates representing a 
negative (no or low expression) population and a positive (or high) expression population were 
constructed such that the negative (no expression, EpCAM-) threshold gate recorded the majority of 
events from the isotype sample while the positive (EpCAM+) threshold gate recorded a population 
corresponding to less than 0.1% of the isotype sample (Figure 4.A). Using the FITC (CD24) and APC 
(CD44) two-colour dot plot of the test sample (containing antibodies specific to CD24, CD44 and 
EpCAM), only the CD44+/CD24- population (Figure 4.B: Quadrant 3 [red rectangle]) was selected for 
EpCAM expression analysis. The threshold PE (EpCAM) fluorescence gates were copied from the 
isotype samples to the corresponding test samples to determine the proportion of CD44+/CD24- 
events displaying EpCAM expression (CD44+/CD24-/EpCAM+) (Figure 4.B). For visual purposes 
the CD44/CD24/EpCAM phenotype analyses have been illustrated as an overlay of the PE (EpCAM) 
isotype fluorescence (Figure 4.C: black histogram) and CD44+/CD24- population PE (EpCAM) 
fluorescence (Figure 4.C: blue histogram). 
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Figure 4| Fluorescent gating strategy for identification of CD44/CD24/EpCAM cell 
populations. 
As only two fluorescence channels can be represented on a single dot plot, the analysis of the CD44/CD24/EpCAM 
phenotype required an additional gating strategy. (A) Using the different population gates (namely Q1 – Q4) from 
Panel I in Figure 3, the isotype control for EpCAM (PE) was displayed on a one-colour histogram (PE; x-axis). A 
negative fluorescence threshold gate was constructed to account for events displaying background fluorescence and 
recorded events displaying low or no expression of the marker (EpCAM-). A positive fluorescence threshold gate was 
constructed such that less than 0.1% of the isotype sample was recorded as displaying positive PE fluorescence. 
Events with PE fluorescence intensities in the range equivalent to the positive fluorescence threshold gate were 
recorded as displaying positive expression of the marker (EpCAM+). The PE fluorescent threshold gates were copied 
onto the respective test samples. (B) For EpCAM expression analysis only the CD44+/CD24- (Q3; red) population was 
analyzed to determine the proportion of CD44+/CD24-/EpCAM+ cells. (C) An overlay histogram of the isotype control 
(black) and the CD44+/CD24- population (blue) from the test sample shows that EpCAM expression was signified by a 
shift of the histogram to the right due to an increase in fluorescence intenity. 
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For each replicate, an isotype control was used to establish the respective fluorescence threshold gates 
(Figure 5.A: Panel I). The MCF-7 breast cancer cell line was found to be comprised of two major and 
two minor cell populations. The major populations consisted of CD44-/CD24- cells representing 
approximately half of the original cell line (55.4%; Figure 5.A Panel II, Q4), and a CD44+/CD24- cell 
population of approximately 32.5% of the original cell line (Figure 5.A: Panel II, Q3). Additionally, 
minor CD44+/CD24+ and CD44-/CD24+ populations of approximately 9% and 2% respectively were 
observed (Figure 5.A: Panel II, Q1 and Q2). Approximately 30% of the total population of MCF-7 
breast cancer cells were determined to be CD44+/CD24-/EpCAM+, as shown by the increase in 
fluorescence intensity and therefore shifts of the blue histogram in Panel III (Figure 5.A) to the right 
of the isotype control histogram (Figure 5.A: Panel III, black histogram).  
 
A different phenotypic profile was observed for the MDA-MB-231 breast cancer cell line, which 
displayed three separate populations of cells based on CD44 and CD24 expression. The major 
population (61.3%) of cells had the CD44+/CD24- phenotype, while the CD44+/CD24+ and CD44-
/CD24- made up 33.3% and 4.88% respectively (Figure 5.B: Panel II, Q3, Q2 and Q1 respectively). 
The 0.49% of cells in the CD44-/CD24+ quadrant was taken as negligible (Figure 3.B: Panel II, Q1). 
The CD44+/CD24- cell population of the MDA-MB-231 breast cancer cell line displayed very low 
EpCAM expression levels (Figure 5.B: Panel III, blue histogram) and therefore most of the cells in Q3 
(representing CD44+/CD24- cells; Figure 5.B: Panel II) were taken as having the CD44+/CD24-
/EpCAM- phenotype. The MDA-MB-231 breast cancer cell line contained almost double (60.97%) 
the percentage of CD44+/CD24- cells compared to the MCF-7 breast cancer cell line (32.5%) (Figure 
5.C), however the CD44+/CD24- MDA-MB-231 breast cancer cells displayed low to negligible 
EpCAM expression (0.35%) whereas the MCF-7 breast cancer cells was determined to have a 
relatively large and statistically significant (p<0.05) CD44+/CD24-/EpCAM+ population (30%, 
Figure 5.C). 
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Figure 5| Expression of CD44/CD24 and CD44/CD24/EpCAM on MCF-7 and MDA-MB-231 
breast cancer cell lines. 
MCF-7 (A) and MDA-MB-231 (B) breast cancer cell lines were stained for the presence of the cancer stem cell markers 
CD44, CD24 and EpCAM and fluorescence detected by flow cytometry using the FACSAria III (BD Biosciences). Cells 
were incubated with fluorophore-conjugated antibodies against CD44 (APC), CD24 (FITC) and EpCAM (PE) or the 
corresponding fluorophore-conjugated isotype controls. In order to determine the CD44/CD24/EpCAM co-expression 
status of cells, the gating strategy shown in Figure 3 and 4 were used to determine the phenotypic profile of the two 
breast cancer cell lines. The live cell population was gated using the forward scatter (FSC) and side scatter parameters 
(SSC) (Figure 3: Panel I) and double colour dot plots representing the expression of CD44 (x-axis) and CD24 (y-axis) 
on the cell lines generated (panel I and II). For both MCF-7 (A) and MDA-MB-231 (B), panel I represents the isotype 
control staining profiles; while panel II represents the corresponding fluorophore-conjugated antibody staining. For 
the two colour dot plot, quadrant gating was applied based on the isotype control staining profile (Figure 3: Panel III 
and IV) and identified four distinct phenotypes (Q1: CD44-/CD24+; Q2: CD44+/CD24+ Q3: CD44+/CD24-; Q4: CD44-
/CD24-) where the numbers represent the proportion of cells within each particular gate. Panel III shows a single 
colour histogram representing the expression of EpCAM (x axis) on the CD44+/CD24- (Q3) subpopulation (number of 
cells represented on the y axis), where the black line indicates the isotype control staining and the blue line indicates 
the EpCAM antibody staining. For the dot plots (panel I and II) and histogram (panel III), the isotype controls were 
used to define the negative and positive gates as described in Figure 3 and 4. Data shown are representative of 
triplicate experiments. The proportion of CD44+/CD24- and CD44+/CD24-/EpCAM+ cells in the MCF-7 and MDA-MB-
231 cell lines was quantified using this approach in triplicate experiments and the average percentage of the different 
populations in the two cell lines is shown in the graph (C). * indicates statistical significance of p < 0.05. 
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3.2.2 Enzyme activity-based (ALDEFLUOR) identification of putative 
BCSCs in MCF-7 and MDA-MB-231 breast cancer cell lines 
 
Putative BCSC populations in the MCF-7 and MDA-MB-231 breast cancer cell lines were 
investigated using the ALDEFLUOR assay (StemCell Technologies). This assay was based on the 
overexpression of active aldehyde dehydrogenase (ALDH), with high expression and activity of 
ALDH1 in particular associated with stem-like cells (Ginestier et al, 2007). The principle of the assay 
centers on the conversion of the ALDEFLUOR reagent (BODIPY-aminoacetaldehyde, BAAA) to the 
green fluorescent BODIPY-aminoacetate (BAA) which is retained within cells. This conversion can 
be measured using flow cytometry by excitation of BAA with the 488 nm blue laser and recording the 
emission in the FITC filter channel. An inhibitor control containing DEAB, a specific ALDH 
inhibitor, can be used to identify cells displaying high FITC fluorescence and hence high ALDH 
activity. 
 
The gating strategy for ALDEFLUOR analyses is represented in Figure 6. A two-colour dot plot 
showing SSC fluorescence on the y-axis and ALDH (FITC) fluorescence on the x-axis was used for 
ALDEFLUOR analyses (Figure 6.A and B). The unstained sample contained no ALDEFLUOR 
reagent and hence displayed no ALDH (FITC) fluorescence (Figure 6.A). The inhibitor control, 
containing 15 µM of the ALDH specific inhibitor DEAB, was used to establish the ALDHHi 
fluorescence threshold gate, which was used to identify events displaying ALDHHi activity (Figure 
6.B: Panel I). The ALDHHi threshold gate was set such that an ALDHHi population of 0.1% or less was 
recorded in the inhibitor control sample (Figure 6.B: Panel II). With the ALDHHi gates set at 0.1% or 
less on the DEAB inhibitor control, individual gates were copied onto the corresponding samples 
without inhibitor in order to determine the proportion ALDHHi events within the sample (Figure 6.B: 
Panel III). Comparison of profiles generated with (Figure 7. A and B: Panel I) and without (Figure 7.A 
and B: Panel II) the ALDH inhibitor (DEAB) allowed for the ALDHHi population to be identified. The 
MCF-7 breast cancer cell line displayed a lower proportion of ALDHHi cells compared to the MDA-
MB-231 breast cancer cell line (Figure 7.A and B), with the MDA-MB-231 breast cancer cell line 
found to display a population of 3.25%, while the MCF-7 breast cancer cell line displayed an ALDHHi 
population of 1.8% (Figure 7.C). 
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Figure 6| Fluorescence gating strategy for ALDEFLUOR enzyme activity-based BCSC 
marker anlyses. 
The ALDEFLUOR assay was visualized using a two-colour dot plot showing side scatter fluorescence (SSC; y-axis) and 
ALDH fluorescence (ALDH fluorescence detected in the FITC channel; x-axis). (A) Unstained samples (sample without 
added ALDEFLUOR reagent) showing no ALDH (FITC) fluorescence. (B) The ALDHHi fluorescence threshold gate was 
constructed using the DEAB (15μM; specific ALDH inhibitor) inhibitor control, with the fluorescence gate set such that 
the inhibitor control sample recorded an ALDHHi population of 0.1% or less (Panel I and II). The fluorescence gate was 
copied onto the corresponding sample lacking inhibitor to identify the ALDHHi population (Panel III)  
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Figure 7| Enzyme activity-based (ALDEFLUOR) detection of putative BCSC populations in 
MCF-7 and MDA-MB-231 breast cancer cell lines. 
Dot plots of side scatter (SSC; y-axis) and ALDEFLUOR fluorescence (ALDH fluorescence detected in the FITC channel; 
x-axis) showing the detection of aldehyde dehydrogenase (ALDH) activity in MCF-7 (A) and MDA-MB-231 (B) breast 
cancer cell lines using the ALDEFLUOR assay enzyme activity-based BCSC profile. Breast cancer cell lines were 
incubated with ALDEFLUOR reagent with (Panel I) and without (Panel II) an inhibitor of ALDH activity (DEAB; 15µM). 
The samples treated with ALDH inhibitor were used to establish the ALDHHi gate with a proportion of staining of 0.1% 
in the inhibited sample being accepted as background (Figure 6). These gates were then copied onto the 
corresponding ALDH without inhibitor samples to identify the proportion of cells showing ALDHHi activity (shown in 
red). The data in (A) and (B) are representative of triplicate experiments (appendix X). The proportion of ALDH high 
cells in the MCF-7 and MDA-MB-231 cell lines were determined in triplicate experiments and the average percentages 
are shown in the graph (C).  
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3.2.3 Anchorage-independent growth of MCF-7 and MDA-MB-231 breast 
cancer cell lines. 
 
The anchorage-independent assay provided a functional-based in vitro technique to enrich for BCSC 
populations. This technique was considered independent of the expression of a single protein marker 
or enzyme activity. The principle of the technique was that cells displaying stem-like properties are 
able to survive and proliferate in serum free conditions within an anchorage-independent environment, 
while non stem-like cells undergo a programmed cell death associated with loss of adherence (known 
as anoikis) (Frisch and Francis, 1994). The anchorage-independent assay has been used for the 
identification and isolation of numerous stem-like cell populations from both normal (Dontu et al, 
2003) and malignant solid tissues (Ponti et al, 2005; Grimshaw et al, 2008; Cariati et al, 2008). For 
the assay, cells are resuspended in a serum-free anchorage-independent medium containing 
specialized growth factors (Materials and Methods 2.1.3). Cells were seeded into ultra-low attachment 
plates and grown for 8 days with the medium being replaced every 3 days. 
 
The MCF-7 and MDA-MB-231 breast cancer cell lines were screened for anchorage-independent 
growth capabilities (Figure 8). Cells from both cell lines were seeded at equivalent numbers as single 
cells (Day 0) and grown for 8 days. For the MCF-7 breast cancer cell line, discrete colonies were 
observed after 4 days of culture with the colonies expanding in size and number by day 8 in culture. 
After 8 days of growth under anchorage independent conditions, the MCF-7 breast cancer cell line 
showed a greater number of anchorage-independent colonies than the MDA-MB-231 breast cancer 
cell line (Figure 8.A). Not only were there a greater quantity of anchorage-independent colonies 
observed in the MCF-7 cell line, but the size of the MCF-7 colonies were greater than that of the 
MDA-MB-231 colonies (Figure 8.A). A time course study of the growth of the MCF-7 breast cancer 
cells in anchorage-independent conditions showed the development of the colonies from single cells 
and continual growth over the 8 day time course (Figure 8.B).  
 
Confocal microscopy was used to perform a morphological comparison of the anchorage-independent 
MCF-7 colonies and adherent MCF-7 breast cancer cells (Figure 8.C and D). Anchorage-independent 
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MCF-7 colonies showed a 3-dimensional spherical morphology, with an apparent concentration of 
cells on the circumference on the sphere, which is consistent with the morphology of mature hollow 
tumourspheres (Figure 8.C). An outer border was apparent in the anchorage-independent colonies 
(Figure 8.C), with cells appearing to line the inside of this border. The nuclei of cells making up the 
anchorage-independent colonies were smaller compared to the nuclei of the adherent cells (Figure 8.C 
and D). The adherent MCF-7 breast cancer cells displayed flattened epithelial morphologies associated 
with adherent cells (Figure 8.D). 
3.2.4 CSC-like and stem cell-like nature of anchorage-independent MCF-
7 colonies. 
 
In order to determine whether anchorage-independent MCF-7 colonies were enriched for BCSCs, the 
expression of CD44, CD24 and EpCAM cell surface markers and the ALDEFLUOR activity of 
anchorage-independent MCF-7 colonies were compared to MCF-7 cells grown under adherent 
conditions (Figure 9). Both anchorage-independent and adherent cells were grown for 8 days, with 
media replacement at the same time. Samples were separated into single cell solutions and analyzed 
for the expression of BCSC cell surface markers. The gating strategies for the CD44/CD24 and 
CD44/CD24/EpCAM staining (Figure 9.A and B) as well as the ALDEFLUOR assay (Figure 9.C and 
D) were performed as described previously (Figure 3, Figure 4 and Figure 6 respectively). Isotype 
controls were used to establish the non-specific and positive expression populations (Figure 9.A and 
B: Panels I and III, black histogram) and DEAB inhibitor controls used to establish the ALDHHi 
populations (Figure 7.C and D: Panel I). The experiments were conducted in triplicate with the 
average proportions of CD44+/CD24- and CD44+/CD24-/EpCAM+ shown in Figure 9.E, and the 
average proportion of ALDH high cells is shown in Figure 9.F. 
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Figure 8| Anchorage-independent growth of breast cancer cell lines. 
Analysis of the growth of breast cancer cell lines under anchorage-independent conditions. (A) MCF-7 and MDA-MB-
231 breast cancer cells were grown in anchorage-independent conditions using modified serum-free breast 
tumoursphere media (as described in Materials and Methods) for 8 days after which representative pictures (images 
captured under 10x objective and 10x eyepiece magnification) were taken of the anchorage-independent colonies. (B) 
Time course study of anchorage-independent MCF-7 breast cancer cell growth in anchorage-independent conditions 
was conducted with representative pictures taken on days 0 (day of seeding), 2, 4, 6 and 8 days of seeding. 
Morphological analysis of anchorage-independent (C) and adherent (D) MCF-7 breast cancer cell cultures. Hoechst 
33342 was used to stain nuclei (blue). Images were captured using either the Nikon Coolpix digital camera or the 
Zeiss LSM510 Meta confocal microscope. Scale bars represent 20μm. 
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Adherent MCF-7 cells displayed a similar CD44+/CD24- profile (approximately 32%) to previous 
analyses (Figure 5.A [Panel II] and C), although a large change was noted between the current and 
previous analyses with regards to the CD44+/CD24+ cell populations. In the previous analyses the 
MCF-7 breast cancer cell line was found to display a minor CD44+/CD24+ cell population (Figure 
5.A: Panel II, Q2) while in the current analyses the CD44+/CD24+ population represented a major cell 
population representing more than half of the original cell line (Figure 9.A: Panel II, Q2). The 
proportion of EpCAM+ cells in the CD44+/CD24- population from the adherent MCF-7 cells was 
found to be greater than 90% (Figure 9.A: Panel III, blue histogram) a result consistent with our 
previous analyses (Figure 5.A: Panel III, blue histogram). The anchorage-independent MCF-7 cells 
displayed an increased CD44+/CD24- cell population (approximately 56%, Figure 9.B: Panel II, Q3; 
Figure 9.E) when compared with the adherent MCF-7 cells, and additionally displayed a larger 
population of CD44+/CD24-/EpCAM+ (approximately 52%, Figure 9.B: Panel III blue histogram; 
Figure 9.E). The CD44+/CD24- and CD44+/CD24-/EpCAM+ populations were both found to be 
significantly increased in the anchorage-independent MCF-7 cells (Figure 9.E, p < 0.05). The adherent 
and anchorage-independent MCF-7 cells showed similar ALDHHi profiles (Figure 9.C and D: Panel II; 
Figure 9.F). Although the anchorage-independent MCF-7 cells showed a greater population of 
ALDHHi, the difference was not determined to be statistically significant. 
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Figure 9| Cancer stem cell-like nature of anchorage-independent MCF-7 breast cancer 
cells 
Comparison of CD44+/CD24-, CD44+/CD24-/EpCAM+ (A and B) and ALDHHi (C and D) populations in adherent (A and 
C) and anchorage-independent (B and D) MCF-7 breast cancer cells. After 8 days of growth, adherent (A) and 
anchorage-independent (B) MCF-7 breast cancer cells were incubated with a combination of directly conjugated 
antibodies against CD44 (APC), CD24 (FITC) and EpCAM (PE). The y-axis in Panel I and II (A and B) represents CD24 
(FITC) fluorescence while the x-axis (A and B: Panel I and II) represents CD44 (APC) fluorescence. The x-axis in Panel 
III (A and B) represents EpCAM (PE) fluorescence. Isotype controls (A and B: Panels I and III [black histogram]) were 
used to establish fluorescent threshold gates as described in Figure 3 and 4.  For ALEFLUOR analyses of adherent (C) 
and anchorage-independent (D) MCF-7 cells, two-colour dot plots of side scatter (SSC; y-axis) and ALDH Fluorescence 
(FITC; x-axis) are shown in Panels I and II. Inhibitor controls (DEAB, 15μM; C and D: Panel I) were used to establish 
ALDHHi threshold gate with gates set as 0.1% or less ALDHHi in inhibitor control (as described in Figure 6) and then 
copied onto the corresponding samples without the inhibitor (C and D: Panel II). All data (A, B, C and D) are 
representative of three independent experiments. The proportion of CD44+/CD24- and CD44+/CD24-/EpCAM+ (E) 
and ALDHHi (F) cells in the adherent and anchorage-independent MCF-7 cells were quantified from triplicate 
experiments and the average percentage of the different populations in the two growth conditions is shown in the 
graphs. * indicates statistical significance of p < 0.05. 
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3.3 Conclusion 
  
We demonstrated that both the MCF-7 and MDA-MB-231 breast cancer cell lines contained 
subpopulations displaying the ALDHHi and CD44+/CD24- BCSC phenotypes, with the MCF-7 cell 
line additionally showing the presence of a CD44+/CD24-/EpCAM+ BCSC phenotype. The MCF-7 
cell line was able to form discrete, three-dimensional tumoursphere colonies when grown under 
anchorage-independent conditions, while the MDA-MB-231 cell line did not. Comparision of the 
expression of CSC markers on the normal and tumoursphere-derived MCF-7 cells showed that MCF-7 
cells grown under anchorage-independent conditions showed an increase in the proportion of cells 
expressing the CD44+/CD24- and CD44+/CD24-/EpCAM+ phenotype, which is consistent with the 
enrichment of CSC populations reported in literature. Although not signifying a BCSC population, 
there was a noted large difference in CD44+/CD24+ MCF-7 populations between the analysis of the 
expression of BCSC phenotypes in breast cancer cell lines (Figure 5.A: Panel II, Q2) and the analysis 
of the cancer stem-like nature of anchorage-independent cells (Figure 9.A: Panel II, Q2). This change 
in phenotype expression may be associated with the prolonged growth of cell growth in vitro. We 
concluded that the tumoursphere-derived MCF-7 cells were enriched in putative CSC populations. In 
order to identify chaperones that may be associated with CSC characteristics, we compared the 
expression of chaperone transcripts in CD44+/CD24-/EpCAM+ enriched tumoursphere-derived cells 
with those identified in MCF-7 grown under normal adherent conditions using a commercially 
available quantitative RT-PCR array.   
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Chapter 4 : Comparison of Molecular 
Chaperone Expression in Adherent 
and CD44+/CD24- enriched 
Anchorage-Independent Populations 
from the MCF-7 Breast Cancer Cell 
Line 
 48 
4.1 Introduction 
 
Quantitative real time PCR (qRT-PCR) is a routinely used technique in cancer research for the 
identification of potential therapeutic targets based on substantial differential gene expression between 
non-cancerous cells and cancer cells, as well as the identification of gene expression signatures that 
correlate with metastatic potential and survival rates (Clarke et al, 2001; Han et al, 2002; Dooley et al, 
2003). qRT-PCR is based on basic PCR principles however as the name suggests, and unlike PCR, 
qRT-PCR analyses product formation after each PCR cycle (Schmittgen and Livak, 2008). Over the 
PCR procedure, product formation undergoes three phases namely the exponential phase, the linear 
phase and the plateau phase. During the exponential product formation phase the concentration of the 
PCR product is increased exponentially. While during the linear and plateau phases PCR reagents 
become limiting factors for product formation. RT-PCR analysis allows for the determination of the 
exponential phases in terms of cycle number (cycle numbers through which exponential 
concentrations of product are produced). The raw measurement provided by the RT-PCR is the cycle 
at which exponential product formation ends and linear phase begins, which is usually set by a 
threshold baseline to ensure comparability amongst all the genes analyzed (Yuan et al, 2006). The 
baseline is set as the line of best fit before the accumulation of any detectable fluorescence above the 
background during the baseline cycles for all samples. The threshold cycle is then calculated by 
subtracting the baseline from the data generated after each cycle for each sample to ensures that any 
changes in background fluorescence do not influence the data. 
 
Analysis of RT-PCR data can be achieved using one of two methods, absolute or relative comparisons. 
Absolute comparison refers to the comparison of the actual concentration of the gene. This technique 
requires the incorporation of concentration standards in the RT-PCR procedure in order to establish 
the concentration of the transcript (Yuan et al, 2006). Relative comparison analysis allows for the 
comparison and identification of changes in the levels of gene expression relative a particular gene, 
usually a housekeeping gene. The gene used for comparative purposes needs to show a constant level 
of expression between samples (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). This 
method compares the relative level of gene expression relative to the state of an unchanged gene.   
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The molecular chaperone gene expression profiles for CD44+/CD24-/EpCAM+ enriched anchorage-
independent MCF-7 and adherent MCF-7 breast cancer cells were analyzed using the commercially 
available real-time reverse transcription (RT2) PCR Array for Heat Shock Proteins (SA Biosciences) 
to determine the relative mRNA abundances of chaperone and chaperone-associated genes. Western 
blot analysis of selected chaperones was performed to compare the abundance of chaperones at the 
protein level relative to the mRNA expression profiles. Comparisons between the anchorage-
independent and adherent MCF-7 breast cancer cells were made in order to identify chaperones, 
particularly members of the DNAJ family of co-chaperones, whose up-regulation or down-regulation 
was associated with anchorage-independent growth. Anchorage independent growth was used to 
isolate populations that were enriched in CSC and therefore any transcripts that were differentially 
expressed in this population could be used to identify putative CSC-specific chaperone genes.  
 
4.2 Results 
4.2.1 Quality control tests and data filtration for RT2 PCR Array of 
anchorage-independent and adherent MCF-7 breast cancer cells. 
 
Relative mRNA abundances of chaperone and chaperone-associated genes were determined using the 
commercially available Heat Shock Protein RT2 PCR Array. The list of genes included in the array is 
shown in Table 2. A schematic diagram showing the RT2 PCR array procedure is shown in Figure 10. 
MCF-7 breast cancer cells were grown under anchorage-independent or adherent conditions (Chapter 
3) for 8 days prior to total RNA extraction using the NucleoSpin RNA/Protein isolation kit 
(Macherey-Nagel). Extracted RNA (1 µg) was converted to cDNA using the RT2 first strand synthesis 
kit (SA Biosciences). Equal amounts of cDNA were loaded in each well of the 96-well RT2 PCR 
Array plate. Data analysis was performed using the online RT2 PCR Array data analysis software 
provided by the manufacturer (SA Biosciences). 
 
To ensure reliability of the analyses, several internal quality control tests were performed (results 
represented in Table 3). Quality control tests evaluated the array reproducibility, reverse transcriptase 
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(RT) efficiency and the potential of genomic DNA contamination. The array reproducibility referred 
to the consistency of the amount of cDNA loaded into each array plate, as well as the efficiency and 
reproducibility of the PCR procedure between the replicates and samples. Array data was reported as 
being reproducible if the positive PCR control (PPC) Ct value of each replicate is approximately 20, 
with a standard deviation less than 2 between arrays. The RT efficiency tested the efficiency of the 
RT2 First Strand cDNA synthesis RT reaction, and allowed for the detection of inefficient conversion 
of RNA to cDNA. As the array primers in each well of the PCR array plate are designed for annealing 
to DNA, the inefficient conversion of RNA to cDNA during the RT2 First Strand synthesis step 
(Figure 10) may negatively affect the mRNA expression analysis by understating the abundance of the 
transcripts. In order to determine the RT efficiency of the PCR Arrays, the average Ct (average of 
replicates of a single sample) of the PPC was subtracted from the average Ct (average of replicates of 
a single sample) of the reverse transcriptase control (RTC), equating to the ∆Ct, for each replicate 
sample. A ∆Ct value of 5 or less showed that the conversion of RNA to cDNA was efficient. In 
contrast, a value greater than 5 shows that there was evidence of inefficient reverse transcriptase action 
and will therefore be reported as failed. As the array primers may also anneal to genomic DNA, the 
presence of genomic DNA may overstate the abundance of transcripts. Genomic DNA contamination 
was evaluated using the Genomic DNA Control (GDC). The GDC Ct value was used to determine the 
presence of genomic DNA contamination, with a Ct of 35 or greater showing the absence of genomic 
DNA (reported as passing) while a Ct between 30 and 35 suggests possible but not certain genomic 
DNA contamination and was reported as an inquiry. Although considered acceptable, a GDC Ct 
ranging between 30 and 35 implied that caution was needed when making conclusions on the data. A 
GDC Ct below 30 was reported as failing the quality control test as genomic DNA is present at a 
concentration that will affect the reliability of the PCR array. 
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Table 2| List of chaperone and chaperone-associated families and genes analyzed on the 
Heat Shock Protein RT2 PCR Array. 
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Figure 10| Schematic diagram of the RT2 PCR Array procedure for the analysis and 
identification of chaperones and co-chaperones displaying differential mRNA levels in 
anchorage-independent and adherent MCF-7 cells. 
I) Anchorage-independent and adherent MCF-7 breast cancer cells were grown for 8 days prior to RNA extraction. (II) 
Total RNA was extracted using the NucleoSpin RNA/Protein kit (Machery-Nagel) and quantified using the 
NanoDrop2000 (Thermo Scientific). (III) The reverse transcriptase reaction (RT-PCR) was performed using the RT2 
PCR First Strand synthesis kit (SA Biosciences) to convert 1 μg mRNA into cDNA for analysis. (IV) Equal cDNA was 
loaded into each well of the 96-well RT2 PCR Array plate with thermocycling performed using the iCycler RT-PCR 
machine (Bio-Rad). (V) Data analyses were performed using online software provided by the manufacturer (SA 
Biosciences).  
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Table 3| Results and outcomes of quality control tests for the RT2 PCR Array of 
anchorage-independent and adherent MCF-7 breast cancer cell line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to achieve statistically significant results, triplicate samples are required. Limitations with 
regards to number of PCR Array plates and the outsourcing of the qPCR machine from another 
university (Nelson Mandela Metropolitan University) meant that the analysis of only two replicates of 
each sample were possible. As such the data analysis has been interpreted cautiously. Nevertheless, 
the repeat samples were found to display reproducible results, with the average Ct of the PPC being 
within the 20 ± 2 value range (20.42±0.16, Table 3) therefore considered as passing the reproducibility 
quality control test. The RT efficiency ∆Ct (average CtRTC – average CtPPC) was calculated to be 4.45 ± 
0.38 (Table 3), below the threshold ∆Ct of 5, suggesting the reverse transcriptase reaction was 
efficient. Although the reproducibility and RT efficiency were reported as passing in the quality 
control tests, the GDC Ct was found to be below the 35 Ct threshold (31.45±0.75, Table 3). However, 
the value was within the 30 to 35 Ct range, that suggested that there was a possibility of genomic 
DNA contamination, a result that may overstate the abundance of certain transcripts, and therefore the 
data were interpreted with caution. Previous optimization of the PCR Array (data not shown) showed 
that a ten-fold decrease in DNA concentration did not change the Ct value to 35 or greater. 
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Based on the results of the QC tests, it was determined that the data could be analysed but that caution 
should be taken when interpreting the data based on the possible genomic DNA contamination. This 
was particularly important in the case of genes that were shown to be highly expressed, where the 
abundance may have been overestimated by the presence of contaminating DNA. Melt-curves, 
analyzing the number of products generated by the PCR, revealed single peaks for each gene 
suggesting that no non-specific amplification had occurred during the analysis (data not shown). All 
transcripts were categorized based on their average Ct values (average between replicates within a 
sample) between the two different samples (anchorage-independent versus adherent). If the average Ct 
of the transcript was below 30 in both test sample (anchorage-independent MCF-7 breast cancer cells) 
and control sample (adherent MCF-7 breast cancer cells) then the gene was classified as class ‘A’ for 
analyses. In cases where the average Ct of a transcript was above 30 in either or both samples, the 
following classifications were attributed to the gene. A gene was categorized as class ‘B’ if the 
average Ct was above 30 in one sample and below 30 in the other sample. These genes showed 
relatively low expression in one sample and were relatively more highly detected in the other sample, 
suggesting that the actual fold-change of the gene between the two samples was likely greater than the 
stated value. However, more replicates would be required to conclusively determine this. Transcripts 
showing average Ct values greater than 30 in both control and test samples were categorized as class 
‘C’. These genes showed relatively low expression levels in both samples and as such the fold-change 
in gene expression between the samples is likely not accurate. Transcripts with Ct values reported as 
ND (not detected), or if the Ct was above the Ct cut-off of 35, in both samples were categorized as 
class ‘D’. These genes were determined as being undetected therefore the fold-change was not 
relevant. The categorized genes are represented in Table 4. 
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Table 4| Class categorization of chaperone and chaperone-associated genes based on 
differential Ct values between sample and the Ct threshold cut-off. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes highlighted in green represent genes showing down-regulation (fold-regulation of -1.5 or less) in anchorage-
independent MCF-7 breast cancer cells. Genes highlighted in red represent genes showing up-regulation (fold-
regulation of 1.5 or greater) in anchorage-independent MCF-7 breast cancer cells. 
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The majority of genes analyzed had a Ct value between 25 – 30 in both samples. This suggested that 
mRNA expression levels of chaperones and chaperone-associated genes were not highly expressed in 
either the anchorage-independent and adherent MCF-7 breast cancer cells (Figure 11.A). However, the 
percentage of chaperone and chaperone-associated genes with a Ct value below 25 (high abundance) 
was lower in the anchorage-independent MCF-7 breast cancer cells, with 34% of genes displaying a 
Ct range below 25 in the anchorage-independent sample, compared to 43.23% in the adherent sample 
(Figure 11.A). The Ct values for the housekeeping genes displayed high reproducibility between 
replicate samples, with β2-macroglobulin, GAPDH and β-actin showing the highest similarities 
between the anchorage-independent and adherent MCF-7 breast cancer cells (Figure 11.B). The β-
actin gene was selected as the housekeeping gene, and subsequent housekeeping protein, used for 
comparative analyses and normalization calculations due to the high reproducibility between replicates 
and high similarity between anchorage-independent and adherent MCF-7 samples. Although RT-PCR 
mRNA expression data is commonly normalized to the expression of more than one housekeeping 
gene, we selected a single housekeeping gene for comparative analysis at both the mRNA and protein 
levels therefore negating the influence of differential abundances of mRNA and corresponding protein 
levels between the two samples. 
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Figure 11| Analysis of gene expression trend of chaperone and chaperone-associated genes 
between adherent and anchorage-independent MCF-7 breast cancer cells and selection of 
housekeeping gene for comparative mRNA expression analysis. 
(A) Proportion of chaperone and chaperone-associated genes within defined Ct value ranges in adherent and anchorage-
independent MCF-7 breast cancer cells. (B) Differential housekeeping gene expression between adherent and anchorage-
independent MCF-7 breast cancer cells. Graphs are representative of duplicate experiments. 
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4.2.2 Differential mRNA expression levels of chaperone and chaperone-
associated genes in anchorage-independent and adherent MCF-7 breast 
cancer cells. 
 
Only class ‘A’ genes (Table 4) were further analyzed for differences in the levels of mRNA 
expression between the two samples. For qPCR analysis, the higher the expression level of a given 
gene, the lower the Ct value. Additionally there is an exponential doubling of the product after each 
cycle. In order to determine the comparative gene expression profile of each chaperone and 
chaperone-associated gene, transcripts across the replicates and between samples were first 
normalized to the housekeeping gene, β-actin, by subtracting the average Ct for β-actin from the Ct 
value of each transcript, the resulting value known as the ∆Ct (Ctspecified gene – Ctaverage housekeeping gene). To 
account for the inverse proportionality and exponential nature of qPCR, the normalized gene 
expression of a gene was represented by 2-∆Ct. The fold-change in gene expression between the 
samples were calculated using the ∆∆Ct method where the ∆Ct of genes from the adherent MCF-7 
breast cancer cell sample were subtracted from the ∆Ct of the corresponding anchorage-independent 
MCF-7 breast cancer cell sample (∆∆Ct = ∆Ct[gene anchorage-independent MCF-7] – ∆Ct[gene adherent MCF-7]). The 
fold-change in the mRNA expression between anchorage-independent and adherent conditions was 
therefore represented as 2-∆∆Ct. For our analyses a fold-change threshold of ±1.5 was used to identify 
genes either up-regulated (a 2-∆∆Ct of 1.5 or greater) or down-regulated (2-∆∆Ct of -1.5 or less). 
 
Gene expression scatter plots were constructed with the Log10(2-∆Ct) of the anchorage-independent 
MCF-7 transcripts plotted on the y-axis, while the Log10(2-∆Ct) of the adherent MCF-7 transcripts 
plotted on the x-axis. These plots were used to compare the expression profile of the different 
chaperone and chaperone-associated families in groups (Figure 12). The fold-regulation threshold was 
set at 1.5. Any genes with a fold-regulation of 1.5 or greater were determined as being up-regulated in 
the anchorage independent MCF-7 cells (Figure 12.A-D: Red circles) while genes with a fold-
regulation of -1.5 or less were determined as being down-regulated in the anchorage independent 
MCF-7 cells (Figure 12.A-D: Green circles). A large proportion of DNAJ genes were found to be 
down-regulated in the anchorage independent MCF-7 cells, including DNAJB12, DNAJC13, 
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DNAJC11, DNAJC9 and DNAJC19 (Figure 12.A: Green circles, and Figure 13.B), with only 
DNAJC12 found to be up-regulated (Figure 12.A: Red circle, and Figure 13.A). Only HSP90AB1 was 
found to be differentially expressed between anchorage-independent and adherent MCF-7 breast 
cancer cells with no HSPA genes showing any detectable difference in expression at the mRNA level 
(Figure 12.B: Green circle). Interestingly there was an apparent down-regulation of the small HSP 
family (HSPB family) in the tumoursphere-derived MCF7 sample, with HSPB8 showing the greatest 
down-regulation (Figure 13.B), as well as HSPH (Figure 12.C: Green circles). The down-regulation 
profile of chaperone and chaperone-associated genes was further reflected in the group of genes 
designated “regulators of protein folding” (RPF) genes, where the majority of genes were down-
regulated in the MCF-7 cells cultured under anchorage-independent conditions as opposed to adherent 
conditions (Figure 12.D: Green circles). Only BAG1 was observed to be up-regulated in anchorage-
independent MCF-7 breast cancer cells (Figure 12.D: Red circle and Figure 13.A). 
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Figure 12| Fold-regulation scatter plots for individual chaperone and chaperone-
associated gene families from Class ‘A’. 
Scatter plots of DNAJs (A), HSP90 and HSPAs (B), HSPH and HSPBs (C) and RPF (Regulators of protein folding, D) 
showing logged β-actin-normalized gene expression levels in anchorage-independent (y-axis) and adherent (x-axis) 
MCF-7 breast cancer cells. Red circles represent genes showing up-regulation in anchorage-independent cells (fold-
regulation of 1.5 or greater). Green circles represent genes showing down-regulation in anchorage-independent cells 
(fold-regulation of -1.5 or less). 
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Figure 13| Chaperone and chaperone-associated genes identified as showing differential 
expression between anchorage-independent and adherent MCF-7 breast cancer cells. 
(A) Genes determined as showing up-regulation in mRNA levels in anchorage-independent MCF-7 cells. Up-regulation 
was determined as a fold-regulation of 1.5 or greater. (B) Genes determined as showing down-regulation in 
anchorage–independent MCF-7 cells. Down-regulation was determined as a fold-regulation of -1.5 or less). 
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4.2.3 Differential protein expression levels of selected chaperone and 
chaperone-associated genes in anchorage-independent and adherent 
MCF-7 breast cancer cells. 
 
To corroborate the finding of the mRNA expression profile of chaperone and chaperone-associated 
genes, the protein levels of selected chaperone and chaperone-associated genes were analyzed in 
anchorage-independent and adherent MCF-7 breast cancer cells. The genes to be analyzed were 
selected both on availability of commercial antibodies to specific chaperone isoforms and the 
difference in mRNA levels between the anchorage-independent and adherent samples. Eight 
chaperone and chaperone-associated genes were selected for protein analyses, including 
HSP90AA1/HSP90AB1, HSPA1A/HSPA8, DNAJB1, DNAJB6, DNAJC6, HSPB1 and BAG1. 
HSP90AB1, DNAJB1, HSPB1 and BAG1 showed differential mRNA expression levels between 
anchorage-independent and adherent MCF-7 breast cancer cells (down-regulation and up-regulation 
respectively; Figure 12.A, B and C). DNAJC6 was down-regulation in the anchorage-independent 
MCF-7 breast cancer cells (Table 4), although the significance of this down-regulation could not be 
determined. HSPA1A/HSPA8 and DNAJB6 were slightly down-regulated in anchorage-independent 
MCF-7 cells, although this down-regulation was not greater than the 1.5 fold-regulation threshold and 
therefore these genes were not highlighted in the previous analysis. Single antibodies recognizing both 
HSP90AA1 and HSP90AB1, and HSPA1A and HSPA8 were used to identify the HSP90 and HSPA 
genes therefore the protein expression levels of the individual HSP90 and HSPA family genes could 
not be determined. 
 
Western blot analyses of specific chaperone and chaperone-associated proteins in anchorage 
dependent and independent MCF-7 cultures are represented in Figure 14. Protein analyses were 
performed in triplicate from independent paired anchorage-independent and adherent growth 
experiments. Actin was used as the protein loading control as previous analyses revealed constant 
Actin expression levels at both the mRNA and protein expression levels, with densitometry performed 
using ImageJ software to account for total protein loading and to determine the relative protein levels 
for comparison between growth conditions (Figure 14.A and B). A decrease in the mean 
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HSP90AA1/HSP90AB1, HSPA1/HSPA8, DNAJB1 and DNAJB6 protein levels was observed in 
anchorage-independent MCF-7 breast cancer cells, compared to adherent MCF-7 breast cancer cells. 
DNAJC6 and HSPB1 protein levels remained constant between the anchorage-independent and 
adherent MCF-7 cells (Figure 14.A and B). All cell lysate samples where quantified prior to analyses 
with equal concentration loaded into each well. Differential Actin protein levels where observed for 
the DNAJB1 and DNAJB6 however this was attributed to differential protein concentration loading 
rather then increased Actin expression. It was therefore necessary to determine the relative values 
normalized to the loading control Actin. Comparisons with the mRNA fold-regulation showed all of 
the genes analyzed at protein level were down-regulated at the mRNA level. HSP90AB1, DNAJB1 
and HSPB1 were down-regulated by more than 1.5-fold in anchorage-independent MCF-7 breast 
cancer cells compared to adherent MCF-7 breast cancer cells (Figure 14.C). DNAJC6 additionally 
displayed down-regulation at the mRNA level, although, as this gene was categorized as class ‘B’, 
further analyses would be required to establish an accurate mRNA expression profile of the gene. 
Several attempts to determine the differential protein expression level of BAG1, identified as being the 
greatest up-regulated gene between anchorage-independent and adherent MCF-7 breast cancer cells 
(Figure 13.A), between anchorage-independent and adherent MCF-7 breast cancer cells were made 
but we were unable to visualize a band corresponding to BAG1 (data not shown). 
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Figure 14| Protein expression levels of selected chaperone and chaperone-associated 
gene from PCR array. 
Western blots (A) and densitometry (B) using Actin as a protein loading control were performed to determined the 
relative protein abundance of selected chaperone and chaperone-associated genes for validation of mRNA profiles 
generated by the RT2 PCR array (Figures 11 and 12). Densitometry analyses performed using ImageJ software. (C) 
Fold-regulation levels of selected chaperone and chaperone-associated genes (Top: selected genes downregulated at 
mRNA level, Bottom: selected genes up-regulated at mRNA level). Grey bars represent genes showing high degree of 
differential fold-regulation.‘+’  represent gene categorized as Class B (Table 3). 
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4.3 Conclusion 
 
The general decrease in the majority of chaperone and chaperone-associated genes was unexpected in 
the context of cancer cells which are often thought to overexpress many chaperones (Calderwood et 
al, 2006). However not all chaperones are stress inducible with many being constitutively expressed in 
cells. Therefore differences in expression profiles may be due to the activity of specific chaperone 
pathways (encompassing specific chaperones) or activity of specific chaperones acting independent of 
canonical chaperone pathways. We identified DNAJB6 has having decreased expression at both the 
mRNA and protein levels in anchorage-independent MCF-7 cells. Previously DNAJB6 expression has 
been shown to negatively affect cancer properties including migration and invasion possibly through 
regulation of the Wnt/β-catenin pathway. The regulatory effect of DNAJB6 on the Wnt/β-catenin 
pathway (primarily due to the regulation of β-catenin levels) additionally influences the epithelial-to-
mesenchymal transition (EMT), a developmental process associated with the generation of stem-like 
cells (Mani et al, 2008). We therefore selected DNAJB6 for further analysis.  
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Chapter 5 : Development of a Tool to 
Study the Role of DNAJB6 in CSC 
Populations 
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5.1 Introduction 
 
DNAJB6 is a type II DNAJ containing a J-domain and G/F rich region. The gene is one of several 
DNAJ genes that have been found to encode for more than one isoform. The DNAJB6 isoforms differ 
by a C-terminal truncation resulting in the absence of a nuclear localization signal (NLS) in DNAJB6S 
(short isoform), a signaling peptide present in DNAJ6BL (long isoform). As such DNAJB6S displayed 
a cytoplasmic localization, while DNAJB6L was located in both the cytoplasm and nucleus (Mitra et 
al, 2008; Zhang et al, 2008). DNAJB6S appeared to be constitutively expressed in cancer cells, while 
DNAJB6L was expressed only in certain cell lines; the expression of DNAJB6L being negatively 
correlated with aggressive properties of the breast cancer in question (Mitra et al, 2008). The tumour 
suppressing properties of DNAJB6L included the inhibition of migration, invasion, soft-agar colony 
formation and tumourigenesis, which has been attributed to the regulatory role played by DNAJB6L in 
the stem cell and CSC associated Wnt/β-catenin signaling pathway (Reya and Clevers, 2005; Mitra et 
al, 2010; Reya et al, 2003; Malanchi et al, 2008; Vermeulen et al, 2010). The regulatory role of 
DNAJB6L, although not fully understood, is thought to arise from DNAB6L expression being 
associated with DKK1 expression. DKK1 is an inhibitor of the Wnt/β-catenin signaling pathway that 
functions by blocking the LRP5/6 Wnt receptor, resulting in the phosphorylation and degradation of β-
catenin leading to inhibition of the Wnt/β-catenin pathway (Reya and Clevers, 2005). The inhibition of 
the Wnt/β-catenin signaling pathway, through DNAJB6L overexpression, reuslted in the loss of 
mesenchymal cell markers and the acquisition of epithelial cell markers including Keratin 18, a known 
DNAJB6L client. Therefore DNAJB6L resulted in a reversion of epithelial to mesenchymal (EMT) 
progression associated with the generation of cells with stem-like properties (Mani et al, 2008) and the 
CD44+/CD24- BCSC phenotype (Morel et al, 2008).  
 
The J-domain of DNAJ contains a highly conserved Histidine-Proline-Aspartic acid (HPD) motif that 
is involved with both the interaction and stimulation of the ATPase domain of HSP70 chaperones 
(Michels et al, 1999). Mutations within this highly conserved motif abrogate HSP70 interaction and 
stimulation therefore preventing classical DNAJ functioning. There is evidence suggesting that 
 68 
DNAJs, especially type III DNAJs containing a varied arrangement and presence of non-classical 
DNAJ domains, have functions additional to and in some cases irrespective of HSP70 stimulation and 
J-domain functionality. Several DNAJ including both type III and type II have demonstrated and 
highlighted the potential of J-domain independent functioning, with none more so then DNAJC17. 
DNAJC17, absence of which is lethal to cells (Sahi et al, 2007), plays a role in mRNA splicing events 
and was shown to function independently of its J-domain with the J-domain only being necessary 
when interactions with partner proteins are compromised (Sahi et al, 2010). Similarly DNAJB8 and 
the smaller isoform of DNAJB6 (DNAJB6S), with both DNAJB8 and DNAJB6 genes encoding for 
similar domain architecture, are both capable of aggregation suppression that is independent of J-
domain activity (Hageman et al, 2010). Recently, our hypothesis of the J-domain dependent tumour 
suppressor activity of DNAJB6L was confirmed by Mitra and colleagues (2012), whereby J-domain 
deletion mutants prevented the tumour suppressor functions of DNAJB6L. Additionally DNAJB6L 
was found carry out its tumour suppressing functions through interaction with HSPA8 (Mitra et al, 
2012). However the J-domain dependent effect on CSC properties remains to be determined. 
 
In this chapter we describe the development of mammalian expression vectors for both isoforms of 
DNAJB6 (DNAJB6L and DNAJB6S) which can be used to study the effect of overexpression of 
DNAJB6 on CSC characteristics of MCF-7 cells. In order to determine whether the effect of DNAJB6 
on CSC properties of MCF-7 cells is dependent or independent of J-domain function, we developed 
DNAJB6 mutants  (DNAJB6L[H31Q] and DNAJB6S[H31Q]) that would lack the ability to stimulate 
the ATPase activity of its partner HSPA. Unlike the mutants described by Mitra and colleagues 
(2012), the mutants produced in our study (DNAJB6L[H31Q] and DNAJB6S[H31Q]) have intact J-
domain but contain a critical mutation abrogating the ability to stimulate the ATPase domain of HSPA 
proteins. 
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5.2 Results 
5.2.1 Sequence analysis of DNAJB6 isoforms DNAJB6L and DNAJB6S 
 
The DNAJB6 gene encodes two isoforms, namely DNAJB6L (large isoform) and DNAJB6S (small 
isoform). DNAJB6L is comprised of 326 amino acids and is approximately 85 amino acids larger than 
the DNAJB6S isoform (241 amino acids; Figure 15.A). The two isoforms show high sequence identity 
(95%), only differing in sequence in the C-terminal (Figure 15.A).  
 
The presence of different protein domains in the two isoforms was analyzed based on sequence 
homology using SMART and PROSITE protein domain search engines (Schultz et al, 1998; Sigrist et 
al, 2010; Letunic et al, 2012). DNAJB6L and DNAJB6S were both found to contain a J-domain (the 
defining domain of DNAJ proteins) and a Glycine/Phenylalanine rich region (G/F; Figure 15.B), both 
domains being characteristic of Type II DNAJ proteins (Kampinga et al, 2009). Additionally the 
presence of histone deacetylase (HDAC) binding domain and an acetylatable lysine has been 
described (Hageman et al, 2010; Kampinga et al, 2010). A nuclear localization signal (NLS) was 
found in the C-terminus of DNAJB6L (Figure 15.B) but was absent from the DNAJB6S isoform due 
to the C-terminal truncation in the smaller isoform (Figure 15.B). As the structures of the DNAJB6 
isoforms have not been resolved, homology modeling using SwissModel was used to predict the 
structure of the J-domain of the DNAJB6 isoforms. SwissModel identified the J-domain of DNAJB3 
as displaying the highest J-domain structure similarity (83.3% identical) to the isoforms therefore this 
was used as the template to model the J-domain of DNAJB6L and DNAJB6S, sharing 100% sequence 
identity. Figure 16 depicts an overlay of the unrefined homology model of DNAJB6 J-domain (Figure 
16; black) produced using SwissMol and the overlay of this model with the model of the DNAJB3 J-
domain using PyMOL (Figure 16; red). 
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Figure 15| Bioinformatic analysis of DNAJB6L and DNAJBS isoforms. 
(A) Alignment of the amino acid sequence of DNAJB6L (NP_490647.1) and DNAJB6S (NP_005485.1) using ClustalW. 
Stars indicate exact amino acid identity between the two isoforms, while dots indicate amino acids of similar charge 
or polarity. (B) Presence of predicted domain structures of DNAJB6L and DNAJB6S using SMART and PROSITE domain 
structure prediction search engines. G/F, Glycine/Phenylalanine rich region; NLS, Nuclear localization signal. 
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Figure 16| Homology model of DNAJB6 J-domain 
(A) Protein primary amino acid sequence alignment of DNAJB6L, DNAJB6S and DNAJB3 using ClustalW. J-domain 
sequence highlighted in box. (B) Unrefined homology modeling of the J-domains of DNAJB6 (black) using SwissModel. 
DNAJB3 J-domain (2ej7, red) was used as the template for the homology modeling due to the 83.3% identity with 
DNAJB6L and DNAJB6S. Models annotated using PyMOL. HPD motif represented in blue. Z-score 1.32. 
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5.2.2 Generation of pCMV-DNAJB6L and pCMV-DNAJB6S mammalian 
expression vectors. 
 
The pcDNA-DNAJB6 plasmids were used as the source of the coding regions for the DNAJB6L and 
DNAJB6S proteins (Hageman et al, 2009). Sub-cloning of the respective coding regions into the 
pCMV backbone was performed to generate the pCMV-DNAJB6L and pCMV-DNAJB6S vectors 
allowing for the expression of the isoforms in mammalian cells as fusion proteins containing an N 
terminal c-myc tag. Figure 17.A shows the plasmid maps of the pcDNA plasmids containing the 
DNAJB6 coding regions and the pCMV-HSJ1a plasmid from which the pCMV backbone was 
isolated. Figure 17.B shows the results of the restriction digestion analysis of the plasmids. The 
identity and presence of the appropriate coding regions was confirmed using BamHI and XhoI 
restriction enzymes, either alone or in combination (Figure 17.B). For both the pcDNA-DNAJB6 
plasmids, the DNAJB6 coding regions were flanked by unique BamHI and XhoI restriction sites 
(Figure 17.A). The HSJ1a coding region in pCMV-HSJ1a was flanked by BamHI restriction sites 
(Figure 17.A). 
 
The uncut plasmid samples (Figure 17.B; lanes 2, 7 and 12) showed the presence of the different 
plasmid conformations (supercoiled, linear and circular). Digestion with either BamHI (Figure 17.B; 
lanes 3 and 8) or XhoI (Figure 17.B; lanes 4 and 9) alone linearized the pcDNA-DNAJB6L and 
pcDNA-DNAJB6S plasmids, resulting in a single band that migrated to the approximate molecular 
weight of the pcDNA-DNAJB6L and pcDNA-DNAJB6S plasmids (approximately 6622 and 6169 bp 
respectively). BamHI digestion alone linearized the pCMV vector (4300 bp) and released a smaller 
DNA fragment corresponding to the expected size of the HSJ1a coding region (approximately 833 bp, 
Figure 17.B; lane 13). The digestion of pCMV-HSJ1a with XhoI produced a single band 
corresponding to the linear size of pCMV-HSJ1a (Figure 17.B; lane 14, 5133 bp fragment). The 
double enzyme digestion using both BamHI and XhoI generated two bands for all three plasmids 
tested, the lower molecular weight bands for each plasmid corresponded to the expected size of the 
coding regions, namely 1020 bp for DNAJB6L (Figure 17.B; lane 5), 725 bp for DNAJB6S (Figure 
17.B; lane 10) and 833 bp for HSJ1a (Figure 17.B; lane 15). 
 73 
 
 
Figure 17| Subcloning of DNAJB6L and DNAJB6S into pCMV mammalian expression vector. 
(A) Plasmid maps of pcDNA-DNAJB6L, pcDNA-DNAJB6S and pCMV-HSJ1a showing plasmid sizes, restriction enzyme 
recognition sites used for subcloning and size of DNAJB6 coding regions. (B) Restriction digestion identification of 
pcDNA-DNAJB6 plasmids and pCMV-HSJ1a and confirmation of the presence of DNAJB6 coding regions. λ Pst 
molecular weight marker: lanes 1, 6 and 11. Uncut DNA: lanes 2, 7, 12. BamHI digestion: lanes 3, 8, 13. XhoI digestion: 
lanes 4, 9, 14. BamHI and XhoI digestion: lanes 5, 10, 15. 
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The DNAJB6L and DNAJB6S coding regions and the pCMV backbone generated by BamHI and 
XhoI sequential restriction enzyme digest (Figure 17.B; lanes 5, 10 and 15) were isolated and used in a 
ligation reaction to generate the pCMV-DNAJB6L and pCMV-DNAJB6S plasmids (Figure 17.A and 
18). The DNAJB6 coding regions were ligated into the pCMV backbone with correct orientation of 
insertion provided by complimentary 5’ and 3’ overhangs created by the BamHI and XhoI restriction 
digestion (Figure 17.A). Ligation reactions were transformed into DH5α E.coli cells and transformants 
were screened for the presence of the DNAJB6 coding regions using BamHI and XhoI single and 
double digestions (Figure 18). All four of the selected DNAJB6L transformants were found to contain 
DNA fragments corresponding to the expected size of the DNAJB6L coding region (1020 bp) and the 
pCMV vector backbone (4300 bp) (Figure 18.A). Both the BamHI and XhoI single enzyme restriction 
digestions of the selected transformants produced single bands representing the expected linear size of 
the pCMV-DNAJB6L plasmid (approximately 5133 bp, Figure 18.A; BamHI: lanes 3, 7, 11, 15; XhoI: 
lanes 4, 8, 12 and 16). The single band generated by the BamHI and XhoI single enzyme digests for 
the pCMV-DNAJB6L transformants were larger than that of the pCMV backbone generated from the 
digestion of the pCMV-HSJ1a control and corresponded to the predicted molecular weight of the 
pCMV-DNAJB6L plasmid (approximately 5133 bp, Figure 18.A; lanes 3, 7, 11 and 15 versus lane 23 
[BamHI], and lanes 4, 8, 12 and 16 versus lane 24 [XhoI]). The digestion of the selected transformants 
using BamHI and XhoI in combination produced two bands (Figure 18.A; lanes 5, 9, 13 and 17). The 
larger band (Figure 18.A; lanes 5, 9, 13 and 17) corresponded to the size of the pCMV backbone 
(4300 bp) and coincided with the pCMV band in the pCMV-HSJ1a BamHI single enzyme (Figure 
18.A; lane 23) and BamHI and XhoI double enzyme digests (Figure 18.A; lane 25). The lower band 
from the double enzyme digests of the selected transformants (Figure 18.A; lanes 5, 9, 13 and 17) 
coincided with the band representing DNAJB6L present in the double enzyme digest from the 
pcDNA-DNAJB6L parental control plasmid (Figure 18.A; lane 21). 
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Figure 18| Subcloning of DNAJB6L and DNAJB6S coding regions into pCMV generating 
pCMV-DNAJB6L and pCMV-DNAJB6S plasmids. 
 
DNAJB6 coding regions and pCMV backbone generated from BamHI and XhoI double enzyme digestions were ligated 
to generate pCMV-DNAJB6L and pCMV-DNAJB6S clones. Transformants of pCMV-DNAJB6L (A) and pCMV-DNAJB6S 
(B) were screened using restriction digestion with BamHI and XhoI in order to identify transformants showing 
positive pCMV-DNAJB6L ligations. λ Pst molecular weight marker: lane 1. Uncut: lanes 2, 6, 10 and 14. BamHI 
digestion: lanes 3, 7, 11 and 15. XhoI digestion: lanes 4, 8, 12 and 16. BamHI and XhoI digestion: 5, 9, 13 and 17. 
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For the pCMV-DNAJB6S plasmid, four transformants were selected and plasmids extracted before 
restriction digestion to identify the presence of the DNAJB6S coding region. For the single enzyme 
digestions of the transformants, single bands coinciding with the pCMV band from the BamHI (Figure 
18.B; lane 23) and double enzyme BamHI and XhoI digestion (Figure 18.B; lane 25) were observed 
(Figure 18.B; BamHI: lanes 3, 7, 11, 15; XhoI: lanes 4, 8, 12 and 16). Additionally double enzyme 
digestion using BamHI and XhoI  (Figure 18.B; lanes 5, 9, 13 and 17) resulted in the generation of two 
bands, the larger band corresponding to the pCMV backbone (approximately 4300 bp, Figure 18.B; 
lane 25) while the smaller band corresponded to DNAJB6S coding region (approximately 725 bp; 
Figure 18.B; lane 5, 9, 13 and 17) and was confirmed by BamHI and XhoI digestion of the pcDNA-
DNAJB6S control plasmid which released a fragment of the equivalent size (Figure 18.B; lane 21).  
 
5.2.3 Site-directed mutagenesis of pCMV-DNAJB6L and pCMV-DNAJB6S J-
domain 
  
Mutation of the histidine residue within the highly conserved HPD motif of the J-domain has been 
previously shown to abrogate the J-domain dependent stimulation of the ATPase domain of Hsp70 
(Michels et al, 1999). We therefore generated H31Q mutants of DNAJB6 by converting the histidine 
of the HPD motif (H31) to a glutamine (Q31). In order to generate site-directed mutants, two 
complimentary primers were constructed integrating a single nucleotide mutation that converted the 
codon coding for H31 (CAT) to Q31 (CAG) (Figure 19.A; red nucleotide). The single amino acid 
change additionally introduced a new BbvI restriction recognition site allowing for the identification of 
H31Q mutants by restriction digest analysis (Figure 19.A, underlined). Nucleotide sequence 
alignments of the H31Q site-directed mutagenesis primers showed complete identity to the DNAJB6L 
and DNAJB6S sequence other than the single nucleotide change (Figure 19.B). 
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Figure 19| Site-directed mutagenesis for the generation of H31Q DNAJB6L and DNAJB6S 
mutants. 
A) Sequences of complementary primers constructed for site-directed mutagenesis to introduce the H31Q single 
nucleotide mutation into the pCMV-DNAJB6S and pCMV-DNAJB6L constructs. Red nucleotides represent the 
mismatch mutation incorporating the H31Q residue change. The single nucleotide mutation incorporated an 
additional BbvI recognition site (underlined) allowing for the identification of H31Q mutants by restriction enzyme 
analysis. (B) Nucleotide sequence alignment of site-directed mutagenesis primers with nucleotide sequence of 
DNAJB6L and DNAJB6S using ClustalW. Stars represent sequences of exact identity. Red nucleotide represents the 
mismatched nucleotide pairing incorporating the H31Q mutation. 
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Site-directed mutagenesis was conducted as described in Materials and Methods. Plasmids subjected 
to site-directed mutagenesis were transformed into DH5α E.coli cells and transformants screened for 
the presence of the H31Q mutation using BbvI restriction analysis (Figure 20). For DNAJB6L, nine 
transformants were screened for the presence of the H31Q mutation. Restriction digest of the parental 
pCMV-DNAJB6L using the BbvI restriction enzyme was used as the control to identify plasmids that 
did not possess the mutation (Figure 20.A; lane 1). Of the nine transformants screened (Figure 20.A; 
lanes 2 to10), four displayed the presence of an additional BbvI recognition site as indicated by the 
band highlighted by the arrow, which was absent in the pCMV-DNAJB6L control (Figure 20.A; lanes 
4, 5, 6 and 10; indicated by arrow). For DNAJB6S, five transformants were screened (Figure 20.B; 
lanes 2 to 6), with only a single transformant displaying the presence of the additional BbvI 
recognition site introduced by the H31Q mutation (Figure 20.B; lane 2; indicated by arrow) compared 
to that of the pCMV-DNAJB6S control (Figure 20.B; lane 1) detected. All plasmids including pCMV-
DNAJB6L, pCMV-DNAJB6S and selected pCMV-DNAJB6L(H31Q) and pCMV-DNAJB6S(H31Q) 
clones (Figure 20.A; lane 6, and Figure 20.B; lane 2) were sequenced to confirm the presence of the 
coding regions and H31Q mutation prior to functional analyses. Sequencing results positively 
identified the presence of the DNAJB6L and DNAJB6S coding regions in the pCMV plasmids (Figure 
21.A). The H31Q mutation in the pCMV-DNAJB6L(H31Q) and pCMV-DNAJB6S(H31Q) were also 
confirmed by sequencing analysis (pCMV-DNAJB6S[H31Q] J-domain shares identicle sequence 
identity therefore the sequencing results were omitted for special requirements, Figure 21.B; boxed 
sequence).  
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Figure 20| Restriction digest identification of H31Q pCMV-DNAJB6L and pCMV-DNAJB6S 
site-directed mutants. 
Following site-directed mutagenesis transformants were screened by plasmids extraction and restriction digestion 
using BbvI in order to identify the presence of the H31Q mutation in the pCMV-DNAJB6L (A) and pCMV-DNAJB6S (B) 
plasmids. λ Pst molecular weight marker: lane M. pCMV-DNAJB6L (A) and pCMV-DNAJB6S (B) controls: lane 1. (A) 
H31Q site-directed mutagenesis clones: lanes 2 – 10. (B) H31Q site-directed mutagenesis clones: lanes 2 – 6. 
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Figure 21| Confirmation of H31Q mutation in pCMV-DNAJB6L and pCMV-DNAJB6S by 
sequencing 
(A) pCMV-DNAJB6L and pCMV-DNAJB6L(H31Q) plasmids were sent to Inqaba Biotech for sequencing using primers 
targeted to the pCMV and T7 promoter. Sequencing alignments (ClustalW) show presence of the single amino acid 
mutation (highlighted by box) incorporating the H31Q mutation in pCMV-DNAJB6(H31Q). (B) Sequence result of 
pCMV-DNAJB6L(H31Q) then under went BLAST analysis (NCBI) identifying DNAJB6L protein with highest identity 
(H31Q single amino acid mutation highlighted in box). Data not shown: pCMV-DNAJB6S(H31Q) sequencing  
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5.3 Conclusion 
 
We were able to successfully clone DNAJB6L and DNAJB6S coding regions into mammalian 
expression vectors enabling the analysis of the effect of overexpression and identification of 
exogenous DNAJB6 through an N-terminal c-myc tag. In order to determine the J-domain dependency 
of DNAJB6 functions, H31Q mutants that would abrogate the ability of the DNAJB6 J domain to 
stimulate the ATPase activity of HSPA were successfully created using site directed mutagenesis and 
confirmed by sequencing analysis. Preliminary analysis can now be undertaken to determine the J-
domain dependency of DNAJB6 regulation of the Wnt pathway and effect of activity on CSC 
properties by transfection of MCF-7 breast cancer cells. Although we showed the presence of the 
H31Q mutation using restriction digestion and sequencing analyses, the abrogation of HSPA ATPase 
stimulation by the mutation remains to be determined. 
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Chapter 6 : Discussion and Conclusions 
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6.1 Discussion 
6.1.1 MCF-7 and MDA-MB-231 contained different CD44+/CD24-
/EpCAM+ subpopulations. 
 
The expression profile of a combination of cell surface markers (phenotype), rather than the 
expression of individual cell surface markers, has been used to identify and isolate CSC populations 
(Al-Hajj et al, 2003; Fillmore and Kuperwasser 2008). Our study revealed that the majority of MCF-7 
breast cancer cells had low or undetectable expression of CD24 (CD24-). What was of particular 
interest was the relatively large CD44+/CD24- population, which differed to the proportion of 
CD44+/CD24- MCF-7 cells reported by other studies (less than 1%, Sheridan et al, 2006; Fillmore 
and Kuperwasser, 2008). The EpCAM expression profile of the MCF-7 cells was characteristic of the 
published data on this cell line (Fillmore and Kuperwasser, 2008), with the vast majority of the MCF-
7 breast cancer cells showing positive EpCAM expression (EpCAM+). Although there have been 
reports that MCF-7 breast cancer cell lines from different laboratories display different biological and 
phenotypic properties (Osbourne et al, 1987), our cell line originated from the same company as that 
described in literature by Fillmore and Kuperwasser (2008) and as such this is unlikely to have 
affected our study. The difference in the phenotypic profile observed may be as a result of the 
environmental conditions and the effects of long-term culture of the cell line. Environmental 
conditions play an important regulatory role in maintaining the stem cell population in normal tissues 
and there is evidence to suggest a similar influence for CSC (Heddleston et al, 2009; Li et al, 2009) 
Additionally there is evidence suggesting that non-stem cancer cells can be induced into displaying 
CSC properties, with this induction regulated by environmental and cellular signals (Roesch et al, 
2010; Chaffer et al, 2011). Nevertheless, our data identified the MCF-7 breast cancer cell line to 
contain relatively large CD44+/CD24- and CD44+/CD24-/EpCAM+ putative BCSC populations. 
 
The MDA-MB-231 breast cancer cell line was found to be comprised almost entirely of CD44 
expressing (CD44+) cells with a relatively high CD24 expressing (CD24+) population compared to 
literature (Fillmore and Kuperwasser, 2008). Previous studies have shown that basal type breast 
cancers, including the MDA-MB-231 cell line, have a characteristically high CD44+/CD24- 
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phenotype (Sheridan et al, 2006; Fillmore and Kuperwasser, 2008; Honeth et al, 2008; Park et al, 
2010; Ricardo et al, 2011). The fact that the MDA-MB-231 breast cancer cell line displayed a higher 
proportion of CD44+/CD24- cells compared to the MCF-7 cell line agreed with reports in the 
literature, the proportion of the population is lower than that described previously (Sheridan et al, 
2006; Fillmore and Kuperwasser, 2008). The MDA-MB-231 cell line was found to be predominantly 
EpCAM-, with the proportion of CD44+/CD24-/EpCAM+ cells making up less than 1%, which is in 
agreement with findings in literature (Fillmore and Kuperwasser, 2008).  
 
One of the major limitations of the use of the CD44+/CD24- phenotype for CSC identification is that 
there are no mechanistic data available to describe why this combination of markers should be 
associated with stem-like characteristics. This raises the question of which is more important – the 
expression of a defined cell surface marker phenotype, or the ability to exhibit the functional 
properties of tumorigenic stem-like cells? Interestingly, the CD44+/CD24- BCSC phenotype depicts 
stem-like cells as displaying no or very little expression of the cell surface marker CD24, while 
mammary stem cells are isolated based on high expression of the CD24 marker (Shackleton et al, 
2006; Vaillant et al, 2008). However while the expression of the gene is not necessary for tumour 
occurrence (Gunther et al, 1991), there is a positive correlation between the enrichment of 
CD44+/CD24- cells after chemo- and radio-therapies and the resistance of putative BCSC to anti-
cancer therapies. The high CD44+/CD24- phenotype in breast cancer has been linked by some authors 
with metastasis through the up-regulation of genes associated with invasion and a stem cell gene 
expression signature (Sheridan et al, 2006; Shipitsin et al, 2007). The MDA-MB-231 breast cancer 
cell line has been reported as having a high metastatic potential as a result of invasive and migratory 
properties (Price et al, 1990). As CD44 has been associated with metastasis (Weber et al, 2002; Kim 
et al, 2004; Brabletz et al, 2005; Balic et al, 2006; Sheridan et al, 2006) it might be expected that this 
cell line would show a high expression level of CD44. Although both the MCF-7 and MDA-MB-231 
breast cancer cell lines contained major CD44+/CD24- populations, the EpCAM expression profile 
distinguished the two cell lines, with the MCF-7 breast cancer cell line being EpCAM+ while the 
MDA-MB-231 cell line being EpCAM-. 
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Some authors have suggested that the proportion of CD44+/CD24- cells within a tumour is a result of 
the cell type from which the cancer originates. As such the cell type origin (basal versus luminal) of 
breast cancers challenges the use of the CD44+/CD24- cell surface phenotype for BCSC identification 
and isolation. The MCF-7 and MDA-MB-231 breast cancer cell lines, although both isolated from 
pleural effusions, are derived from different mammary epithelial cell type origins. The MCF-7 breast 
cancer cell line originates from luminal type cells (expressing luminal keratins) while the MDA-MB-
231 breast cancer cell line, a highly metastatic cell line, originates from basal type cells (expressing 
stratified epithelial keratins) (Sorlie et al, 2001; Sorlie et al, 2003). Basal and luminal breast cancers 
have been shown to display differential CD44/CD24 cell heterogeneity, with basal breast cancers 
showing characteristically high CD44+/CD24- expression. Breast cancer cell lines of luminal origin 
have been found to be almost entirely comprised of CD24 expressing cells (CD24+), with less than 
1% of the population displaying the CD44+/CD24- phenotype associated with BCSCs (Sheridan et al, 
2006; Fillmore and Kuperwasser, 2008; Ricardo et al, 2011). Additionally, Fillmore and Kuperwasser 
(2008) showed the CD44+/CD24- phenotype was a characteristic of the cytokeratin expression status 
of the breast cancer using breast cancer cell lines, where basal breast cancers showed CD44+/CD24- 
enrichment whereas luminal breast cancer cell lines had a low CD44+/CD24- population. It was 
concluded that in luminal breast cancer cell lines, where high EpCAM expression was a feature (as 
shown in our study using the MCF-7 cell line), BCSCs were sufficiently enriched in the 
CD44+/CD24- population. With basal breast cancer cell lines, the enrichment and isolation of BCSC 
could be obtained in the EpCAM+ population (Fillmore and Kuperwasser, 2008). Taking this into 
account, we found the MCF-7 breast cancer cell line to show a greater proportion of cells with the 
‘luminal’ BCSC phenotype (CD44+/CD24-) compared to MDA-MB-231 cells displaying the ‘basal’ 
BCSC phenotype (EpCAM+). Both luminal and basal cell types originate from mammary epithelial 
stem cells (Villadsen et al, 2007). However, evidence suggests that BCSCs may not have definitive 
cell surface markers because BCSC populations from spontaneous murine breast tumours can be 
isolated using different non-overlapping cell surface marker CSC phenotypes (CD44+/CD24- and 
CD133+) (Wright et al, 2008). Although displaying different non-overlapping markers, these CSC 
populations displayed identical stem-like biological properties (Wright et al, 2008).  
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6.1.2 MCF-7 and MDA-MB-231 contained similar ALDEFLUOR profiles. 
 
The MDA-MB-231 cell line showed a higher ALDHHi population compared to the MCF-7 breast 
cancer cell line. The ALDHHi population has been used to identify stem-like cells from both normal 
and malignant breast tissue (Ginestier et al, 2007). The proportion of ALDHHi cells in both MCF-7 
(1.8%) and MDA-MB-231 (3.25%) was marginally greater than the 1% reported in previous studies 
(Charafe-Jauffret et al, 2009a). Ginestier and colleagues (2007) concluded that in vivo 
tumourigenicity, the defining CSC property (Clarke et al, 2006), was exclusive to ALDHHi cells. They 
proposed that the tumourigenic potential of the CD44+/CD24- BCSC population due to the presence 
of ALDHHi cells in this population (CD44+/CD24-/ALDHHi cells) meaning that tumourigenicity and 
CSC enrichment could be obtained irrespective of the CD44+/CD24- phenotype as there was no 
correlation between the two populations (Al-Hajj et al, 2003; Ginestier et al, 2007). Additionally there 
were a greater proportion of ALDHHi cells in basal cancers compared to luminal cancers (Charafe-
Jauffret et al, 2009a) suggesting a greater proportion of BCSC in basal cancers. Fluctuations in 
absolute percentages within the ALDHHi population were observed and may have arisen from 
environmental changes or growth phase differences between samples. Although CSCs are maintained 
in the population through symmetric cell division, it remains to be determined whether the population 
is dynamic or maintained at a constant proportion of the tumour mass, however the recent description 
of the spontaneous induction of non-stem cancer cells into a CSC-like state suggests that the CSC 
population is dynamic (Chaffer et al, 2011) 
6.1.3 MCF-7 breast cancer cells were capable of anchorage-independent 
growth. 
 
Anchorage-independent studies revealed that the MCF-7 breast cancer cell line was capable of 
forming anchorage-independent colonies in serum free conditions. The anchorage-independent MCF-7 
colonies showed typical three-dimensional morphologies associated with anchorage-independent 
growth with spherical cell clustering (Dontu et al, 2003; Ponti et al, 2005, Cariati et al, 2008). 
Colonies additionally displayed morphological characteristics of embryoid bodies with the presence of 
a distinct outer membrane resembling the zona pellucida of a developing embryo (Bleil and 
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Wasserman, 1980). In contrast, the MDA-MB-231 cell line displayed a very low frequency of 
anchorage-independent colony formation after 8 days of growth. This was interesting with respect to 
the cell surface marker-based and enzyme activity-based identification data. As the MDA-MB-231 
breast cancer cell line was found to be enriched in cells displaying the BCSC phenotype 
(CD44+/CD24-) as well as having a larger  (although not statistically significant) ALDHHi population, 
it was presumed that the MDA-MB-231 cell line should have a greater proportion of cells capable of 
anchorage-independent growth. However, we found no correlation between the size of the 
CD44+/CD24- population and anchorage-independent growth properties. Additionally there was no 
correlation between ALDHHi proportion of cells and anchorage-independent colony formation. There 
was an apparent correlation between the CD44+/CD24-/EpCAM+ phenotype and anchorage-
independent growth properties, suggesting that the CD44+/CD24-/EpCAM+ phenotype is more 
discriminating of BCSC characteristics. The observation that the MCF-7 breast cancer cell line 
portrayed a greater proportion of cells capable of anchorage-independent growth agreed with the 
suggestion that BCSCs from basal breast tumours are present in the EpCAM+ population, while 
BCSCs from luminal breast tumours are present in the CD44+/CD24- population (Fillmore and 
Kuperwasser, 2008).  
6.1.4 Anchorage-independent MCF-7 cells were enriched in 
CD44+/CD24- and CD44+/CD24-/EpCAM+ cells. 
 
Anchorage-independent colonies isolated from malignant breast tissues have been shown to be highly 
enriched, (>90% in certain cases) in CD44+/CD24- cells (Ponti et al, 2005). The anchorage-
independent MCF-7 colonies obtained during this study were found to be enriched in CD44+/CD24- 
cells compared to anchorage-dependent (adherent) MCF-7 cells, with almost a 2-fold increase in the 
population. This increase in CD44+/CD24- cells suggested that the colonies were enrichment in 
BCSC-like cells, a result in agreement with previous studies (Ponti et al, 2005). Although there was 
little change observed in the proportion of ALDHHi cells between adherent and anchorage-independent 
MCF-7 cells, our previous data showed a lack of correlation between ALDHHi proportion of cells and 
anchorage-independent growth characteristics. The increase in CD44+/CD24- cells suggested the 
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enrichment of putative CSCs in anchorage-independent cells when compared to MCF-7 cells grown 
under normal conditions (adherent MCF-7 cells).  
 
The stem-like nature of the anchorage-independent MCF-7 colonies could have been confirmed by 
probing for the expression of pluripotency markers, such as Oct-4, c-Myc and Sox-2. These 
transcription factors form part of the transcription factor cocktail capable of transforming murine and 
human adult fibroblast cells into induced pluripotent cells (Takahashi and Yamanaka, 2006; Takahashi 
et al, 2007). Oct-4 has been shown to be up-regulated in anchorage-independent colonies (Ponti et al, 
2005) and  c-Myc was required for the proliferation and survival of cancer stem cells in glioma (Wang 
et al, 2008), Leis and colleagues (2011) recently showed that Sox-2, and not Oct-4, overexpression 
was characteristic of anchorage-independent growth with knockdown of Sox-2 preventing anchorage-
independent cell growth (Leis et al, 2011). Therefore the analysis of the levels of these pluripotency 
markers in the anchorage-independent colonies would support the conclusion that tumoursphere 
derived cells were enriched in cells with stem-like characteristics.  As in vivo tumour formation is seen 
as the most important CSC characteristic (Clarke et al, 2006), the concluding experiment would be in 
vivo xenotransplantation assays in limiting numbers to confirm the tumorigenicity of the isolated 
populations where CSC-enriched population would display the exclusive in vivo tumour formation 
ability. 
6.1.5 Down-regulated molecular chaperone gene expression profile. 
 
The CD44+/CD24- phenotype remains the most widely accepted phenotype for the identification of 
BCSC. We showed evidence of BCSC phenotype enrichment in anchorage-independent MCF-7 cells 
with the CD44+/CD24- and CD44+/CD24-/EpCAM+ BCSC-associated phenotypes. We used the 
tumoursphere-derived MCF-7 cells as representative of a CSC-enriched sample for the analysis of 
chaperone gene expression. The expression of a number of molecular chaperones in adherent and 
anchorage independent MCF-7 colonies was compared using a commercial quantitative RT-PCR array 
system. The mRNA expression pattern of the chaperone and chaperone-associated genes in the MCF-7 
breast cancer cell line, in general, showed that the majority of genes had low mRNA levels (Ct > 25) 
suggesting that not all chaperones were constitutively expressed in cancer cells. Using a fold 
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expression threshold of ± 1.5 fold between adherent MCF-7 and anchorage-independent cells, a 
number of genes were identified as being differentially regulated in the putative CSC-enriched 
populations. Of the total 84 genes analyzed, 22 were found to be down-regulated (< -1.5 fold) in 
anchorage-independent MCF-7 breast cancer cells while 2 genes were found to be up-regulated (< 1.5 
fold) and 60 showed little to no change in mRNA levels between the two samples. Ideally an 
additional comparison with normal non-cancerous mammary cells and somatic mammary stem cells 
would have allowed for the identification of cancer-specific chaperones and stem-cell specific 
chaperones. Currently we cannot attribute the observed profile solely to the anchorage-independent 
state of the cells, as there may be inherent similarities between normal tissue cells and anchorage-
independent cells. 
6.1.6 Several DNAJ were down-regulated at the mRNA level in 
anchorage-independent MCF-7 cells. 
 
The majority of the down-regulated DNAJ were of the type III (DNAJC) classification. This may be 
expected due to the fact that this particular DNAJ class contains the largest number of members 
(approximately 32) (Kampinga and Craig, 2010). However, the down-regulation of type III DNAJ 
may also indicate the activation or inactivation state of different cellular pathways in cancer and 
BCSC-like cells (Sterrenberg et al, 2011). Type III DNAJ are the most structurally diverse of the 
DNAJ classes and indeed of chaperone and chaperone-associated gene families in general. The 
diversity of DNAJ is evident in the sizes of the different isoforms (often greater than 40 kDa) and the 
domain architecture. It is thought that type III DNAJ have highly specific and stringent substrate 
binding domains, while type I and II show a more relaxed substrate binding domain (Kampinga and 
Craig, 2010). As such, the down-regulation of a specific type III DNAJ isoform may suggest a change 
in specific client proteins (DNAJ substrates) that are processed by particular chaperone pathways in 
anchorage-independent cells compared to adherent cells. Therefore chaperone-dependent processing 
of proteins may act as a post-translational regulatory event.   
 
Several DNAJ have been identified as showing differential mRNA expression levels in BCSC 
populations (summarized in Table 5). Both DNAJB1 and DNAJC13 were found to have differential 
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expression profiles in CD44+/CD24- BCSC and normal breast tissue (although it was not stated 
whether these proteins were up-regulated or down-regulated) (Liu et al, 2007). Our study showed that 
both these genes were down-regulated in anchorage-independent MCF-7 cells. As we observed that 
anchorage-independent MCF-7 cells were enriched in CD44+/CD24- cells, our finding may 
corroborate that of Liu and colleagues (2007). The expression of DNAJB1 is regulated by HSF1, the 
heat shock protein transcription factor (Jacobs and Marnett, 2007), which was also additionally found 
to be down-regulated in our study. DNAJC9 was up-regulated at the RNA level in anchorage-
independent BCSCs (Rappa and Lorico, 2010) and at the protein level in human embryonic cells (Van 
Hoof et al, 2006). However we found the DNAJC9 transcript to be down-regulated in our study. 
DNAJC19 showed decreased RNA levels in ALDHHi BCSC (Charafe-Jauffret et al, 2009a), a result in 
line with observations in our study that showed a decrease in DNAJC19 in the BCSC enriched 
anchorage-independent MCF-7 cells. In addition, our study identified a number of other DNAJ 
(DNAJB6, DNAJB12 and DNAJC14) that were down-regulated but have not been reported in the 
CSC gene expression literature (Table 5). The major limitations of this study along with most 
microarray analyses is that they do not account for the presence of isoforms or splice variants of 
genes. While there are 49 DNAJ genes, there is likely to be over 49 functioning DNAJ proteins due to 
several DNAJ genes encoding for numerous splice variants including DNAJA3, DNAJA4, DNAJB2, 
DNAJB5, DNAJB12, DNAJB14, DNAJC2, DNAJC7, DNAJC12 and DNAJC19. Splice variants of 
DNAJ genes have been shown to display opposing functions, as is the case for DNAJA3 isoforms 
whereby DNAJA3L (larger isoform) increased apoptosis while DNAJA3S (smaller isoform) 
decreased apoptosis in osteosarcoma cells treated with mitomycin C and Tumour Necrosis Factor-α 
(Cheng et al, 2005). Additionally for DNAJB6, the two isoforms display a differential subcellular 
localization with DNAJB6L located in both the cytoplasm and nucleus while DNAJB6S is located in 
the cytoplasm (Zhang et al, 2008). 
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6.1.7 HSP70 regulating proteins, DNAJC12 and BAG1, were up-regulated 
in anchorage-independent MCF-7 cells. 
 
Only two genes were shown to be up-regulated (> 1.5 fold) in anchorage-independent MCF-7 cells, 
with both genes (DNAJC12 and BAG1) being regulators of the HSPA family of chaperones. 
DNAJC12 is an estrogen target gene that has been found to be up-regulated at the RNA level in ER+ 
compared to ER- breast cancers (De Bessa et al, 2006) and in ER+ anchorage-independent breast 
cancer cells compared ER+ parental cell lines (Kok et al, 2009). The MCF-7 breast cancer cell line is 
ER+ (Neve et al, 2006) and therefore the upregulation of DNAJC12 may be indicative of an increased 
activation of the estrogen signaling pathway in the anchorage-independent cells.  
 
Table 5| Differential DNAJ expression in stem-like cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modified from Sterrenberg et al, 2011. 1 AIG BCSC enriched in CD44+/CD24- phenotype. 2 Gene expression 
comparison made between CD44+/CD24- BCSCs and normal breast tissue. AIG, Anchorage-independent growth 
isolated. BC, Breast cancer. BCSC, Breast cancer stem cells. ER+, Estrogen receptor positive. hESC, Human embryonic 
stem cells.  
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BAG1 showed the greatest up-regulation of all chaperone and chaperone-associated genes in the 
anchorage-independent MCF-7 cells. The BAG family of proteins are nucleotide-exchange factors 
(NEF) that are involved in the removal of ADP from the ATPase domain of HSPA proteins and 
replacement with ATP (Sondermann et al, 2001). This process of nucleotide exchange resulted in the 
release of the client protein from HSPA. BAG NEFs therefore function in HSPA client processing in a 
manner opposite to the function of DNAJ co-chaperones, and thus aid in the regulation of HSP70 
function (Kampinga and Craig, 2010; Takayama et al, 1997). The overexpression of BAG1 has been 
observed in numerous cancer cells (Takayama et al, 1998); where members of the BAG family 
provided protection against apoptosis and environmental stresses including hypoxia, radiation and 
chemotherapeutic agents through the stabilization of Bcl-2 family proteins (Townsend et al, 2003). 
BAG1 has been shown to interact with heparin-binding EGF-like growth factors; both heparin and 
EGF are components of the anchorage-independent medium (Lin et al, 2001; Dontu et al, 2003). The 
protection against apoptosis and environmental stresses are perceived attributes of putative BCSCs, 
therefore supporting a possible role for BAG1. However, no correlation has been found between 
BAG1 mRNA and protein levels. It has been,suggested that BAG1 was post-translationally regulated 
(Townsend et al, 2002) and as we were unable to determine the protein level of BAG1, whether this 
up-regulation at the mRNA level correlated with up-regulation at the protein level in anchorage-
independent cells remains to be determined (data not shown). A thorough proteomics analysis 
(confirming the expression state of the genes at the protein level) could be performed for the majority 
of genes in this study. The link between transcription and protein expression is highly contentious, 
with evidence suggesting that there is no correlation between protein and mRNA levels (Gygi et al, 
1999).  
6.1.8 DNAJB1 and DNAJB6 isoforms were down-regulated at both the 
protein and mRNA levels in anchorage-independent MCF-7 cells. 
 
In order to validate the RNA expression profile, selected genes were analyzed at the protein levels 
using commercially available antibodies. The protein levels were normalized to β-actin protein levels. 
Decreased protein levels correlated with the down-regulation at the mRNA level for all of the genes 
analyzed (HSP90AA1/HSP90AB1, HSPA1A/HSPA8, DNAJB1, and DNAJB6), with the exception of 
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DNAJC6 and HSPB1 where the protein levels remained relatively constant. Studies have shown that 
chaperones are highly expressed in cancer cells compared to normal tissue cells (Chant et al, 1995; 
Ciocca et al, 2005). It was therefore interesting to note that both the constitutively expressed cytosolic 
HSP90β isoform, HSP90AB1, and the stress-inducible HSP90α isoform, HSP90AA1, showed 
decreased mRNA levels (greater than -1.5 fold and less then -1.5 fold respectively) in the anchorage-
independent cells. Protein analysis using an antibody that detects both isoforms identified a decrease 
in protein levels in anchorage-independent MCF-7 cells compared to adherent MCF-7 cells. However 
whether this was due to a change in a single HSP90 isoform or decrease in both isoforms remains to 
be determined. The decrease in the mRNA expression of DNAJB1 and DNAJB6 was confirmed at the 
protein level.  
6.1.9 Development of a tool to study the role of DNAJB6 isoforms in 
cancer stem cell biology. 
 
DNAJB6 is expressed as two isoforms, namely the DNAJB6L and DNAJB6S isoforms. For DNAJB6, 
the 85 amino acid truncation results in the loss of the NLS in DNAJB6S therefore the isoforms 
displays differential subcellular localization. The differential subcellular localization is likely to 
expose the DNAJB6 isoforms to different client proteins. Therefore, presuming that the C-terminal 
truncation does not result in the loss of important non-classical domains, the biochemical activity is 
likely to be the same, although the biological functions of the different DNAJB6 isoforms may vary. 
Hageman and colleagues (2010) found that DNAJB6S was capable of interaction with HDAC 
proteins. The truncation may not influence the activity of the C-terminally located HDAC binding 
domain present in DNAJB6 isoforms (Hageman et al, 2010). While there was a loss of a lysine rich 
portion of the protein which is likely to be acetylatable in DNAJB6L, DNAJB6S does contain several 
lysine residues in the unique sequence located at the extreme C-terminus of this isoform.  
 
DNAJB6 expression has been found to negatively affect breast cancer properties, leading to decreased 
migration and invasion. Expression of the DNAJB6L isoform has been correlated with Wnt signallng 
regulation (Mitra et al, 2008; Mitra et al, 2010). The fact that a decrease in DNAJB6 was observed in 
the anchorage-independent MCF-7 cells suggested that the activated Wnt/β-catenin pathway may be 
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involved in anchorage-independent growth. The H31Q mutants of each isoform were generated in 
order to investigate whether the activity of DNAJB6 isoforms was dependent on the stimulation of 
HSPA ATPase activity. Mutation of the conserved HPD motif of the J domain is known to inhibit the 
J-domain dependent stimulation of HSPA ATPase activity (Michels et al, 1999).  
 
We have developed a tool to determine whether the effect of DNAJB6 expression on both cancer cells 
and the CSC population was dependent on a functional J-domain. In order to carry out this functional 
analysis of DNAJB6 expression on the BCSC population, breast cancer cells will be transfected with 
the mammalian expression vectors (generated during the study) and analysis of the proportion of the 
CD44+/CD24-, CD44+/CD24-/EpCAM+, ALDHHi an anchorage-independent cells will be evaluated 
as described previously. As several studies have identified the possible mechanisms behind DNAJB6 
tumour suppressor functions, potential insight may be provided if DNAJB6 was found to affect BCSC 
populations. In addition, the requirement of a functional J-domain may provide a possible drug target 
through the DNAJ J-domain stimulation of HSPA mechanism.  These data will complement the recent 
findings of Mitra and colleagues, who showed that deletion of the J domain of DNAJB6L impaired the 
biological function (Mitra et al, 2012). While the authors propose that this mechanism was as a result 
of the loss of interaction with HSPA8, it is possible that deletion of the entire J domain (amounting to 
approximately one third of the protein) may have resulted in structural changes to DNAJB6 that 
resulted in the loss in activity. Our H31Q mutant constructs should possess a similar structure to the 
wild type protein and indicate whether the functional activity of DNAJB6 is dependent on the 
stimulation of HSPA ATPase activity.  
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6.2 Conclusions and Future Perspectives 
 
We have demonstrated that the isolation of breast cancer cells from the MCF-7 breast cancer cell line 
based on anchorage-independent growth enriched for cells displaying the putative CD44+/CD24- and 
CD44+/CD24-/EpCAM+ BCSC phenotypes. In order to accurately identify this population as being a 
BCSC population, further analyses are needed to characterize the expression of markers of 
pluripotency, such as Oct4 and Sox2. Confirmation of the tumorigenic nature of the anchorage-
independent MCF-7 breast cancer cells should be verified by in vivo tumour formation experiments. 
The molecular chaperone gene expression revealed several chaperone and chaperone-associated genes 
as being down-regulated in anchorage-independent MCF-7 breast cancer cells. As chaperone and 
chaperone-associated gene have been described as cellular regulators, the downregulation of several 
chaperones may highlight changes in signaling pathways and cellular processes that distinguish 
BCSC-like cells from non-stem breast cancer cells. As regulators of signaling pathways and cellular 
processes, chaperone and chaperone-associated genes may present potential targets to inhibit or 
alternate the pathways or processes thus leading to the differentiation or cell death of the 
therapeutically important cancer cell population. Further proteomic analysis would be required to 
confirm the gene expression data and to determine whether the differential mRNA levels are of 
biological significance. The identification of DNAJB6 as showing decreased mRNA and protein levels 
was interesting due to the effect that the DNAJB6 large isoform (DNAJB6L) has on the Wnt pathway, 
a pathway known to play an important role in stem-like nature of both normal tissue stem cells and 
CSCs. The affect of DNAJB6 on CSC biology has not been established. We have developed a tool to 
study the affect of the overexpression of DNAJB6 isoforms on cancer cells in order to determine how 
DNAJB6 expression would influence the CSC population. Although confirmation of the gene 
expression analysis at the protein level is required for many of the genes identified as displaying 
differential expression between non-CSC and CSC-enriched cell populations in breast cancer, this 
study does suggest that specific chaperone and chaperone-associated genes are required for the CSC-
like biological functioning of CSCs. 
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Appendix Table 1| Antibody and suppliers used in this study. 
 
 
 
 
 
 
 
 
 
